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Scientific environment 
The present work was performed in the Clinical Immunology Research group in 
cooperation with the Department of Dermatology at Stavanger University Hospital. 
The Clinical Immunology Research Group, headed by professor Roald Omdal 
focuses largely on the neurological aspects of chronic inflammatory autoimmune 
diseases, and especially the biological mechanisms of chronic fatigue. The group has 
resources to organize studies, and to collect and store data and biological samples, 
and has access to a well-equipped, staffed research laboratory with Luminex and 
electrochemi-luminescence platform (MSD) for cytokine analyses that was used in 
the current project. The group has a number of international partners. The present 
work started in 2012, financed by a grant from the Stavanger Health Research. The 
majority of the work in this thesis was mainly conducted in the period from 2016 to 
2019 when I received financial support as a doctoral research fellow from the 
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Fatigue is prevalent in patients with chronic inflammatory diseases and often rated as 
the most troublesome aspect of their disease. Clinical experience indicates that 
fatigue is common also in patients with psoriasis, but studies are sparse.  
A model for understanding fatigue is the "sickness behavior model" in animals. 
Following the onset of an infection a coordinated set of behavioral changes occurs in 
the sick animal, commonly recognized as lethargy, depression, loss of thirst, hunger, 
and reduction in grooming. Fatigue is a prominent and dominant feature of this 
response. This behavior is signaled by interleukin (IL)-1β in the brain, and has many 
similarities with chronic fatigue in humans. Chronic inflammatory disease resembles 
a "chronic infection". Thus, fatigue is continuously induced through "danger signals" 
triggering the innate immune system and leading to a “sickness behavior response”.  
Although activation of the innate immune system and IL-1β play pivotal roles in 
generation of fatigue, other immune regulatory mechanisms have been suggested as 
potential mediators. The frequent reported lack of association between disease 
activity and fatigue in chronic inflammatory diseases is a paradox that could be 
explained by involvement of down-regulatory immune mechanisms and responses 
involved in protection against cellular stress. However, the entire biological 
mechanisms of fatigue are yet poorly understood.  
Fatigue can be challenging for the patients to live with and for the clinicians to treat. 
There is a lack of management guidelines. Evidence suggest that biological drugs 




• Write a review article with focus on current knowledge, biological 
mechanisms and identifying research gaps on fatigue in psoriasis 
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• Investigate and describe fatigue in chronic plaque-type psoriasis patients and 
compare with age- and gender matched healthy subjects to obtain a better 
understanding of the extent and severity of this phenomenon 
• Estimate the efficacy of biological drugs on fatigue in psoriasis  
• Uncover biological processes and signaling pathways that cause fatigue in 
psoriasis. 
o Investigate plasma levels of markers of oxidative stress in psoriasis 
patients compared to healthy subjects, and explore the associations with 
fatigue  
o Investigate plasma levels of selected cytokines in psoriasis patients 
compared to healthy subjects, and explore the association with fatigue 
o Compare gene expression of selected heat shock protein genes in 
psoriasis patients with high and low fatigue levels  
 
 
Subject and methods 
 
Fatigue was measured in 84 patients with chronic plaque-type and 84 age- and 
gender-matched healthy subjects. The patients were recruited from the Department of 
Dermatology, Stavanger University Hospital and the healthy subjects were 
predominantly recruited form acquaintances of the patients. Fatigue severity was 
assessed using three different generic fatigue instruments: the fatigue Visual Analog 
Scale (fVAS), the Fatigue Severity Scale (FSS), and the Short Form 36 (SF-36) 
vitality scale. Cut-off scores were defined as ≥50 for fVAS, ≥4 for FSS, and ≤35 for 
SF-36 vitality scale. Disease activity was evaluated using the Psoriasis Area and 
Severity Index (PASI), and the impact on quality of life (QoL) with the Dermatology 
Life Quality Index (DLQI).  
 
To investigate oxidative stress, we measured plasma levels of advanced oxidation 
protein products (AOPP) and malondialdehyde (MDA) in plasma using UV-
spectrophotometry and high performance liquid chromatography connected to a 
fluorescence detector.  
 8
 
Plasma levels of IL-1β, IL-1Rα, IL-6, and IL-10 were measured by 
electrochemiluminescence based Meso Scale Discovery assay, IL-1RII by  
sandwich enzyme-linked immunosorbent assay. 
 
Peripheral blood transcriptional profiles of HSP genes from 10 patients with high 
fatigue and 10 patents with low fatigue were compared. The expression levels of four 
of these genes (HSPB11, HSPA14, HSP90B1, HSP90AB1) were re-evaluated by 
reverse transcription quantitative real-time polymerase reaction in 20 patients with 




We found that: 
 
• Fatigue is overlooked and an under-researched phenomenon in psoriasis.  
• Nearly 50% of psoriasis patients suffer from clinically important fatigue. 
Fatigue severity is associated with pain, depression and smoking, but not with 
psoriasis disease severity 
• Biological drugs have a small to moderate effect on fatigue in psoriasis 
• Plasma concentrations of AOPP and MDA are not associated with fatigue in 
psoriasis patients. These biomarkers of oxidative stress are not increased in 
psoriasis patients compared to healthy subjects. Plasma AOPP and MDA are 
strongly dependent on gender and other non-disease related factors. Several 
physiological and methodological factors influence concentrations of AOPP 
and MDA 
• Plasma concentrations of IL-1β, IL-1Rα, IL-1RII, IL-6, and IL-10 are not 
associated with fatigue. Plasma concentrations of IL-1Ra and IL-6 were 
influenced by BMI, not disease severity in psoriasis patients 
• Fatigue is associated with altered expression of some HSPs. A tendency to 
higher expression levels of HSPB11 and lower expression of HSP90B1 is 
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demonstrated in patients with high fatigue scores compared to those with low 
fatigue scores.  
 
Conclusions 
Fatigue is common and severe in psoriasis patients. Fatigue is strongly associated 
with pain and depression, but not with disease activity. There is a modest positive 
effect of biological drugs. Fatigue is not related to plasma markers of oxidative stress 
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1. Background 
1.1 Psoriasis  
1.1.1 Epidemiology and clinical presentation  
Robert Willan (1757-1812), a British dermatologist, is considered to have given the 
first detailed clinical description of psoriasis in his publication “On cutaneous 
diseases” in 1808, and thereby distinguished psoriasis from other similar skin 
conditions (1).  
 
Psoriasis is an immune-mediated chronic inflammatory skin disorder affecting about 
2% of the Western population. The prevalence varies according to geographical 
regions of the world (2), and in Scandinavian countries a large span ranging from 2% 
to 11% has been reported (3, 4).   
 
The most common clinical variant is plaque-type psoriasis (also known as psoriasis 
vulgaris) representing about 85% to 90% of patients. This variant is characterized by 
sharply demarcated, occasionally painful and itchy, erythrosquamous plaques with 
predilection to extremities and the lower back. The severity of the disease can be 
highly variable ranging from minor signs to overt clinical manifestations. Other less 
prevalent clinical variants of psoriasis include guttate (droplet) or eruptive psoriasis 
in which there are usually numerous very small teardrop shaped plaques; pustular 
psoriasis which can be grouped into generalized pustular psoriasis and localised 
forms including palmoplantar pustular psoriasis and acrodermatitis continua of 
Hallopeau. Erythrodermic psoriasis is a term used when more than 80% of the skin is 
involved. This condition is sometimes life-threatening, and can develop in any type of 
psoriasis (5). The different clinical variants may be overlapping, or one type may 
transform into another clinical type. They can be further divided into sub-phenotypes 
according to distribution, anatomical localisation, size and thickness of plaques, onset 
and disease activity (6). 
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The histopathological features of the psoriatic plaque show keratinocyte 
hyperproliferation (epidermal hyperplasia) with dysfunctional differentiation 
overlying dermal inflammatory cell infiltrates consisting of dermal dendritic cells, 
macrophages, T-cells and neutrophils. The presence of neutrophils into the epidermis 
is one of the hallmark histological features of psoriasis (5). 
 
1.1.2 Genetics  
A genetic basis has long been acknowledged in psoriasis. There is a higher incidence 
of psoriasis among relatives of psoriasis patients than in the general population, and 
about 30% of patients have an affected first degree relative (6). If a co-twin has 
psoriasis, monozygotic twins are more likely to have psoriasis than bizygotic twins 
(7).  
 
Psoriasis is an autoimmune disease (8). An autoimmune disease is a condition in 
which the immune system is autoreactive, i.e. T-cells or B-cells or both, recognize 
bodily molecular structures (epitopes) as foreign (non-self). Psoriasis is considered a 
mainly T-cell driven disease, although B-cells and other parts of the complex immune 
system such as the innate immune system involving macrophages, dendritic cells and 
cytokines, are more or less involved in the attack on skin elements (9).  
 
The majority of autoimmune diseases are linked with the human leukocyte antigen 
(HLA) system (10). “HLA” is the designation used for the human version of the 
major histocompatibility complex, a set of genes that code for cell surface proteins 
essential for the acquired immune system to recognize foreign structures in 
vertebrates (11). The HLA complex in humans consists of more than 200 genes 
located close together on the short arm of chromosome number 6 (6p21). The gene 
complex can be categorized into three different classes. Proteins produced from HLA 
class I genes are expressed on the surface of nearly all nucleated cells, while proteins 
produced from HLA class II genes are typically present on the surface of antigen-
presenting cells (monocytes, macrophages and dendritic cells), B-cells and activated 
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T-lymphocytes. HLA class III contains genes coding for immune responses like the 
complement system, cytokines and heat shock proteins (HSPs). Classically, HLA 
class I and II proteins present peptides for T-cells. Genetic variants/polymorphisms in 
the HLA complex locus have been shown to influence susceptibility to most 
autoimmune diseases. Educating the immune system to distinguish between self and 
non-self is a vital step in preventing autoimmunity. However, self-reactive T-cells 
may escape the negative selection in thymus and be activated by complexes of certain 
HLA molecules and self-peptides (12).  
 
The most common genetic loci linked to psoriatic susceptibility are found within the 
HLA gene complex. HLA-Cw6 is the major risk allele, also known as the psoriasis 
susceptibility locus 1 (PSORS1) (13). HLA-Cw6 is present in more than 60% of 
psoriasis patients, and increases the relative risk for psoriasis from 9 to 23 fold 
depending on heterozygosity or homozygosity (14).  
 
Notably, the majority of autoimmune diseases are multigenic, i.e. an unfortunate set 
of variants of immune response genes are necessary for disease development. 
Genome wide associations studies (GWAS) have identified several loci outside the 
HLA region that increase the risk for psoriasis, but with much lower strength of 
association than the PSORS1 gene (15). The PSORS2 is another chromosomal locus 
with linkage to psoriasis. Recent studies have shown that this is due to mutations in 
the CARD14 gene on chromosome 17q25 (16). CARD14 mutations influence 
psoriasis susceptibility by activation of NF-kB and upregulation of a subset of 
psoriasis-associated genes in keratinocytes (16).  
 
Single nucleotide polymorphisms (SNP)s are substitutions of one base pair with 
another. The majority of the SNPs are found in non-coding regions of the genome 
and only some of the substitutions influence biological functions (17). Various SNPs 
located close to genes involved in immune regulation as well as in skin barrier 
function have been associated with increased risk of psoriasis (18). Multiple gene loci 
involving the interleukin (IL)-23 pathway are also associated with increased risk of 
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psoriasis e.g. IL-12B, IL-23A, IL-23R, tumor necrosis factor alpha induced protein 3 
(TNFAIP3), TNF receptor associated factor interactive protein 2 (TRAF3IP2), and 
signal transducer and activator of transcription (STAT) 3.  
 
The variety of clinical manifestations seen in psoriasis reflects differences in genetic 
setup. HLA-Cw6 is strongly linked to early and acute onset psoriasis, but is not 
associated with pustular psoriasis (19, 20). Loss of function mutations in IL36RN 
which encodes an antagonist to the IL-36 receptor, have been linked to pustular 
psoriasis, but not plaque-type psoriasis (21). IL-36 belong to the IL-1 pro-
inflammatory cytokine family (22). 
 
Overall, no single genetic variant seems to be sufficient to account on its own for the 
development of disease, and a complex interplay between many genetic loci is 
required. Also, several SNPs associated with psoriasis are overlapping with other 
immune mediated conditions like Crohn´s disease, celiac disease and ankylosing 
spondylitis, and illustrates that there is a genetically predisposed tendency to develop 
autoimmune disease in general, and that the distinct diseases are not inherited per se 
(14). 
 
1.1.3 Epigenetics  
However, the lack of a clear and strong inheritance pattern indicates that genetic 
predisposition might not be the only factor contributing to disease. Environmental 
factors are thought to be contributors or triggers for development of autoimmune 
diseases. Exposure to certain drugs and viral infections are examples of factors that 
influence how genes are read or translated. DNA is wrapped around histone protein 
complexes. Histone proteins can be modified by several processes that influences 
accessibility of chromatin to the transcriptional complex. Such epigenetic 
modifications influence gene expressions without changing the genomic sequence, 
and may add to the disease risk. Important epigenetic mechanisms include DNA 
methylation, histone modifications, and microRNA (miRNA).  
 20
 
DNA methylation is a biochemical process in which a methyl group (CH3) is added 
from the carbon-5 position of cytosine in a cytosine base to create a 5-
methylcytosine. DNA methylations commonly occur at sites in the promoter and 
enhancer regions of genes, and prevent transcription of a gene. This results in 
suppressed expression (silencing) of that gene.  
DNA hypomethylation (demethylation) means removal of one or more methyl groups 
from cytosine bases and has the opposite effect of methylation. This process can 
activate or increase the expression of a gene that was previously silenced or reduced 
in activity (23).  
 
The consequences of histone modifications for transcription depend on the specific 
combinations of modifications, i.e. what type of histone protein, specific amino acid 
and type of modifications involved. Some modifications are associated with active 
transcription while others are associated with silencing (23).  
 
miRNAs are small evolutionarily conserved, noncoding RNAs. They base pair with 
complementary sequences within mRNA molecules and regulate gene expression at 
the posttranscriptional level. This will usually lead to downregulation of the gene 
expression.  
 
Epigenetics changes have been observed in psoriatic skin cells as well as in 
peripheral blood cells of psoriasis patients (24). A decrease in number of methylation 
sites in genes involved in epidermal function and differentiation has been 
demonstrated in lesional psoriatic skin tissue which mapped to genes highly 
upregulated in psoriasis (25). Multiple miRNAs have been found to be aberrantly 
expressed in psoriatic skin of which some are likely to influence key processes in 
psoriasis pathogenesis including epidermal differentiation and inflammation (26).  
These findings support an epigenetic contribution in gene regulation relevant to the 
psoriasis pathophysiology 
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1.1.4 Immunopathophysiology 
The IL-23/Th17 axis along with TNF-a is considered to play a dominating role in the 
disease pathophysiology of the chronic phase of psoriasis (27). IL-23 drives the 
expansion and activation of Th17 T cells that produce IL-17, and therapeutic agents 
targeting IL-17 and IL-23 signalling are highly effective and result in rapid and 
substantial improvement in about 90% of patients (28).  
 
 
Figure 1. The TNF-a/IL-23/Th17 and keratinocyte interplay in psoriasis.  
After activation from a trigger factor, dendritic cells (DC) and macrophages (MC) are stimulated and 
secrete inflammatory mediators that lead to differentiation of Th1/Th22/Th17 cells. T cells release 
key inflammatory cytokines that stimulate keratinocytes to an abnormal hyperproliferation. Activated 
keratinocytes produce antimicrobial peptides (AMP), chemokines and cytokines that lead to 
subsequent amplification of the psoriatic skin process.  
 
Although the chronic stage of psoriasis is predominantly featured by an adaptive 
immune response, there is a complex interaction between the innate and the adaptive 
immune responses. Key cytokines in psoriasis, e.g. interferon (IFN), IL-12, IL-22 and 
IL-23 activate janus kinase (JAK) and signal transducer and activator of transcription 
(STAT) intracellular pathways. JAKs are localized at the intracellular region of cell-
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surface receptors. Once a proinflammatory cytokine or another ligand binds to its 
receptor, JAKs phosphorylate and activate downstream signalling pathways including 
STATs. Activated STATs translocate to the nucleus and activate target genes 
resulting in modulation of proinflammatory gene  transcription (29). Furthermore, 
extracellular stimuli can activate nuclear factor kappa-light-chain enhancer of 
activated B cells (NF-kB), another inducible transcription factor that orchestrates 
inflammation involved in the psoriasis pathogenesis (13). These signalling pathways 
are common in many chronic inflammatory conditions.  
 
During the early phases of psoriasis development, IFN-g seems to play a pivotal role. 
IFN-g is also a predominating inflammatory cytokine in unstable and acute forms 
such as erythrodermic psoriasis or guttate-type psoriasis (8). Increased concentrations 
of IL-1b , IL-36a and IL-36g  have been found in pustular psoriasis compared to 
psoriasis vulgaris (30). Neutrophils, which are found in low numbers in the epidermis 
and stratum corneum in chronic plaque lesions, are the dominating leukocytes in 
pustular psoriasis. Neutrophils are key inducers of the IL-36 group of cytokines 
which triggers IL-1b production in dendritic cells. Although, IL-17 signalling is also 
operative, the IL-36/IL-1 pathway seems to have an important role in pustular 
psoriasis. 
 
Altogether, adaptive mechanisms seem to be in the foreground in stable and mild 
disease while innate mechanisms seem to be more prominent in patients with active 
disease. The active signalling pathways in plaque psoriasis and the other clinical 
variants may well be overlapping, and the abovementioned separation is not absolute. 
Nevertheless, separation of the different signalling pathways might shed light on the 
immunophysiological reasons for why one therapeutic approach is effective in some 




1.1.5 Immune activation 
It is hypothesized that an altered microbiota may trigger an immune activation in 
autoimmune disease. Microbiota is a term meaning all bacteria, vira, or other 
microorganisms that colonize different areas of the body such as the skin, nasal 
cavities, oral cavities, the gut, eyes and genitourinary tracts. Several skin diseases, 
including psoriasis, reveal a differential colonizing microbiota compared to healthy 
skin (31). It is possible that the skin microbiome plays a regulating role by 
stimulating the production of antibacterial peptides. Proliferating keratinocytes in 
psoriasis patients overexpress antimicrobial peptides such as LL37 (a 37 amino acid 
C-terminal cleavage product of the antimicrobial peptide, cathelicidin), b-defensin 
and S100A7 (psoriasin) (32). Antimicrobial peptides could alter the skin microbiome 
and resistant microbial species to these antimicrobial peptides could be favoured (33). 
LL37 was the first antimicrobial peptide identified in mammalian skin. Physical 
trauma (cell damage) or bacterial products can trigger release of extracellular self-
nucleic acids (DNA and RNA) and LL37 from damaged cells. Self-nucleic acids 
forms complexes with LL37. These complexes stimulate dendritic cells through toll 
like receptor (TLR)s, but can also be presented by HLA-Cw6 molecules and 
specifically activate T-cells (34). Further research is required to explore the more 
exact role of the microbiome in the pathogenesis of autoimmune diseases. 
 
Furthermore, it has been suggested that reactive oxygen species (ROS) are involved 
in  psoriasis pathophysiology (35). ROS are reactive molecules which can damage 
cell components such as proteins, carbohydrates, lipids and DNA, and are important 
weapons that innate immune cells use to kill pathogens. The body has a well-
controlled defence system to counterbalance these highly reactive molecules and 
during normal physiological conditions there is a balance between oxidants and the 
ability to detoxify these reactive molecules. However, in inflammatory conditions 
there is an increased production of ROS. These molecules can increase the production 
and release of proinflammatory cytokines through activation of NFkB (31). Oxidative 
stress is defined as an imbalance in which ROS dominate over the antioxidant 
defence system.  
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1.1.6 Associated disorders 
Psoriasis may not be limited to the skin only. Psoriatic arthritis occurs in 20% to 30% 
of patients (36, 37). Other coexisting conditions include, but is not limited to, obesity, 
cardiovascular disease, diabetes mellitus and inflammatory bowel disease (38). The 
total comorbid disease burden increases with increasing psoriasis disease severity 
(39). Several studies have shown that patients with severe psoriasis have increased 
mortality, most commonly caused by cardiovascular disease (CVD) (40, 41). The 
increased risk of CVD may be due to the increased systemic inflammation. However, 
there is also an over-representation of general risk factors for CVD such as smoking, 
hypertension, dyslipidaemia, obesity and diabetes (42). Incomplete adjustments for 
traditional risk factors will consequently form uncertainty regarding to what extent 
the skin disease itself is an independent risk factor for CVD.  
 
1.1.7 Quality of life  
The physical and emotional burden associated with psoriasis affects daily life and 
work, even in patients with mild disease (43, 44). Psoriasis is known to deteriorate 
quality of life (QoL) to the same degree as other major chronic illnesses such as heart 
disease and diabetes (45). The psoriatic patients frequently encounter problems with 
depression and anxiety, alcohol abuse and smoking (46-48).  
 
Depression plays a major role to the lower QoL (49). Inflammatory mechanisms 
involving pro-inflammatory cytokines have been implicated in the aetiology of 
mental illness (50). Epidemiological evidence demonstrate an increased prevalence of 
mood disorders also in patients with autoimmune conditions other than psoriasis, and 
the relationship between inflammation and depression is gaining increased attention 
(51). The World Health Organizations defines QoL as an “individual´s perception of 
their position in life in the context of the culture and value systems in which they live 
and in relation to their goals, expectations, standards and concerns” (52). QoL covers 
the physical, functional, emotional and social-well-being of the patient (53). This is a 
highly subjective experience by definition and is therefore measured by self-report 
 25 
questionnaires. Patient reported outcome measures are key assessments tools which 
are increasingly being emphasized in clinical trials of psoriasis patients.  
 
1.1.8 Treatment  
Therapy is administered according to disease severity. Topical corticosteroids and 
vitamin D3 analogues are usually sufficient to achieve adequate improvement in cases 
with mild disease. Topical calcineurin inhibitors are used for localized difficult to 
treat sites such as the face and intertriginous areas. If not sufficient effect of topical 
therapy alone, UVA/UVB phototherapy can be applied to induce remission (5). 
 
Systemic treatment with immunomodulating drugs is indicated in moderate to severe 
disease. The therapeutic spectrum is relatively broad and includes cyclosporine, 
methotrexate, acitretin, fumaric acid esters which are often used as first line of 
treatment. Since the beginning of this century there has been a substantial increase in 
systemic psoriasis treatment regimens. While previous conventional drugs influenced 
the immune system in a more or less non-specific manner, biological drugs that 
directly targeted specific inflammatory mediators lead to a marked improvement in 
treatment effects. The TNF-a inhibitors infliximab, etanercept and adalimumab were 
the first biologic agents to be approved for psoriasis. From 2009 onwards the IL-12 
and -23 antibody ustekinumab, the IL-17 inhibitors (secukinumb, ixekizumab and 
brodalumab) as well as the IL-23 inhibitors (guselkumbab, tildrakizumab and 
risankizumab) have emerged (54). With these highly effective, specific targeted 
drugs, the treatment goal has moved towards complete skin clearance of psoriasis 
(55). One disadvantage is that biological drugs are large molecular drugs (>1000Da) 
and need to be administered by injection. New small molecular drugs which directly 
target immune regulating checkpoints have emerged in the past decade. These drugs 
have the advantage that they can be administered orally, due to cutaneous 
permeability they could potentially also be formulated for topical administration, and 
they are less expensive to produce (8). To date small molecule drugs have shown 
moderate efficacy compared with biologics in psoriasis. Apremilast, a 
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phosphodiesterase-4 inhibitor, and tofacitinib, a JAK inhibitor, have demonstrated 
reduction of psoriasis disease activity in clinical trials, the latter was only FDA 
approved for psoriatic arthritis (PsA) and not for plaque type psoriasis only. 
However, there are more small molecule drugs currently undergoing clinical testing.  
  
The presence of comorbidities such as PsA and inflammatory bowel disease is highly 
relevant when treatment options are considered. The responses to immune 
modulating treatments vary within individuals with the same disease and disease 
severity. This is likely caused by different genetic setup and immune signaling 
pathways. It has for example been demonstrated that HLA-Cw6 positive patients 
respond better and more quickly to ustekinumab than patients with other psoriasis 
susceptibility polymorphisms.  
 
Precision medicine is a strategy in which medical treatment is tailored to “the 
individual characteristics of each patients”. Patients can be subclassified into groups 
that differ in their response to specific treatment based on their individual genetic, 
epigenetic and molecular characteristics (56). In the future this will obviously 
optimize treatment response, reduce health costs and potential side effects and 
individualize care for patients with psoriasis (57). 
 
Despite all of these effective therapeutical options available, still many psoriasis 
patients remain untreated. A multinational survey of psoriasis and psoriatic arthritis 
revealed that 80% of psoriasis patients with moderate to severe disease are treated 









1.2 Fatigue  
1.2.1 Definition  
Fatigue is a subjective experience, and has been defined as “an overwhelming, 
debilitating, and sustained sense of exhaustion that decreases one´s ability to carry 
out daily activities including the ability to work effectively and to function at one´s 
usual level in family and social roles” (59). Fatigue is associated with reduced 
motivation and is also recognized as “the failure to initiate and/or sustain attentional 
tasks and physical activities requiring self-motivation” (60). Fatigue can be 
distinguished from the normal tiredness everyone can feel during stressful periods in 
life by not being restored by sleep. In a qualitative study intending to capture the 
difference between fatigue and normal tiredness in patients with primary Sjogren’s 
syndrome, patients reported that fatigue was often experienced as a feeling of bodily 
heaviness and could unexpectedly fluctuate in intensity (61). Importantly, patients 
suffering from fatigue therefore have to adjust their activity according to these flares. 
 
1.2.2 Fatigue in chronic diseases  
It has been said that a patient suffering from fatigue could have nearly any condition 
listed in a joint edition of the Oxford textbook of Medicine and Psychiatry (62).Yet, 
for the patients it is vitally important and often rated as the most troublesome 
phenomenon of their disease (63).  
 
Fatigue is common in depression, hypothyroidism, chronic sleep disorders, cancer 
and chronic neurological diseases. In chronic inflammatory diseases such as Crohn´s 
disease, primary Sjögren’s syndrome (pSS) and rheumatoid arthritis, the prevalence 
can often be up to and above 50% (64-66) .  
 
Fatigue should be separated from myalgic encephalomyelitis/chronic fatigue 
syndrome (ME/CFS) in which no other underlying condition associated with fatigue 
can be identified (67). Only a small minority of patients presenting with chronic 
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fatigue have ME/CFS, the vast majority having a recognized or unrecognized 
underlying disease or condition. The prevalence of this disorder has been estimated to 
be 0.4% and 2.6% in community and primary care-based studies respectively (68, 
69).  
 
There is an unclear relationship between disease activity and the severity of fatigue. 
In chronic inflammatory diseases some studies show an association between 
increased fatigue and increased disease severity. Notably, use of generic fatigue 
instruments that lack disease associated items, frequently fail to demonstrate such an 
association (70, 71).  
 
While psychosocial aspects have been widely studied in dermatological diseases, less 
is known about fatigue. There are only a few genuine studies on fatigue in psoriasis, 
and the majority of available data are from therapeutic clinical trials investigating 
new biological agents.   
 
1.2.3 Measurement  
Fatigue is a subjective experience hence difficult to measure. Objective markers for 
fatigue do not exist. Instruments measuring this phenomenon are therefore based on 
self-reporting, and most instruments are questionnaires. Some are unidimensional, 
while others attempt to measure several aspects or domains of fatigue, e.g. central, 
peripheral, cognitive, etc. Some instruments are disease specific, and thus validated 
only for one single condition. Such instruments also capture disease specific factors 
other than fatigue like elements associated with disease activity, pain and 
inflammatory items. Other fatigue measuring questionnaires are intended to be used 
across a number of diseases, and referred to as generic instruments. There is no 
consensus regarding the optimal choice of instrument to use. The generic 
unidimensional instruments; Fatigue Visual Analog Scale (fVAS), Short Form 36 
Health Survey Vitality Subscale (SF-36 VS) and the Functional Assessment of 
Chronic Illness Therapy-Fatigue Scale (FACIT-F) have been extensively applied by 
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our research group, is easy to use, short and simple to interpret, sensitive to change 
over time, and is widely accepted (72).  
 
1.2.4 Consequences  
Chronic fatigue is often rated by the patients as their most debilitating phenomenon, 
and has a major impact on QoL (63, 73). Fatigue has substantial sosio-economical 
implications as it can lead to long term sick leave and work disability (74). Fatigue 
can lead to social withdrawal, and can be background for conflicts both at home and 
at work. Many patients do not acknowledge fatigue as a symptom of their underlying 
disease and may therefore interpret themselves as being lazy. Excessive rest and day 
time sleep can create a disturbed sleep cycle which results in increased perceived 
fatigue levels. A vicious circle between distorted sleep rhythm and experienced 
fatigue may therefore become inevitable.  
 
1.2.5 Mechanisms for fatigue  
There is an increasing understanding of the neurobiological basis of disease 
associated fatigue. A conceptual model for a scientific understanding of fatigue is the 
“sickness behavior response”. This is a coordinated set of behavioural changes seen 
in all animals during infections and bodily harm. The behaviour is characterized by 
weariness, fatigue, reduced appetite, -thirst, -initiative, -grooming, -social activities, 
and depressed mood. Fatigue is a prominent feature of this response. In an 
evolutionary perspective this represents a strongly conserved and complex survival 
mechanism, and is supposed to protect the animal from predators while the immune 
system is fighting the pathogen. It therefore increases the probability that genes are 
forwarded to the new generations. In this regard, sickness behaviour is not a 
maladaptive response, but a subconscious strategy for the survival of the individual 
and the species (75).  
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Although the underlying biological mechanisms for fatigue is not fully understood, 
emerging evidence points to a key role for the innate immune system. One major 
source for activation of the innate immune system is stimulation by pathogen 
associated molecular patterns (PAMPs) and damage-associated molecular pattern 
(DAMPs) molecules. PAMPs are evolutionary conserved structural motifs found on 
bacterial cells walls, DNA, lipoproteins or other structures on pathogens, while 
DAMPs represent the body´s own biomolecules released by damaged or dying cells. 
Innate immune cells react to PAMPs and DAMPs through activation of pattern 
recognition receptors (PRRs). TLRs are one type of PRRs, C-type lectin receptors, 
nucleotide-binding oligomerization domain-like receptors and retinoic acid inducible 
gene-I-like receptors are other examples. Activation of innate immune cells like 
macrophages, dendritic and granulocytes follows and leads to production of pro-
inflammatory substances like IL-1, IL-6 and TNF-a (76).  
 
Several studies have revealed that IL-1b is a key cytokine for induction of sickness 
behaviour in animals (59). Despite being protected by the blood brain barrier (BBB), 
the central nervous system (CNS) is influenced by peripheral inflammation. 
Peripherally produced IL-1b enter into the brain through active and passive transport 
systems across the BBB (50). IL-1b  can also be produced intrathecally by activated 
microglia in response to systemic stimuli (77). Inside the brain IL-1b binds to a 
complex of IL-1 receptor type 1 (IL-1RI) and the brain isoform of IL-1R accessory 
protein (IL-1RAcPb) on cerebral neurons (78). This does not cause inflammation, but 
leads to neuronal activation, followed by sickness behavior, in which fatigue is a 
prominent feature (79). Notably, IL-1R1 knock out mice are resistant to sickness 
behavior (80).   
 
Whereas more thoroughly studied in animals, also clinical studies in humans 
highlight a fundamental role of IL-1b in promoting sickness behavior. Up-regulation 
of IL-1 in the brain is seen in a variety of acute and chronic disease (81). 
Furthermore, treatment with IL-1 blocking agents has been shown to alleviate fatigue 
 31 
in rheumatoid arthritis, pSS, Cryopyrin-Associated Periodic Syndromes, cancer, and 
diabetes type 2 (82). 
 
Although IL-1b it is important for generation of fatigue, it is possible that other 
immune regulatory mechanisms as well as cellular stress responses are potential 
mediators (83). One hypothesis for alternative fatigue generation is through oxidative 
stress mechanisms that occur in acute and chronic inflammatory diseases (84). 
Oxidative stress results from an imbalance in which ROS dominate over antioxidant 
defences. One mechanism to protect the cells against oxidative stress and other 
inducers of cellular stress is through upregulation of heat shock proteins (HSPs). 
HSPs are highly conserved proteins present in all animals and plants. They are mainly 
found intracellularly and have housekeeping, as well as protective roles in situations 
of different cellular stresses. Some HSPs are secreted out of the cells, have signaling 
properties and regulate functions in other cells. Extracellular HSPs influence 
immunological functions and some can activate TLRs (85, 86). Binding of 
lipopolysaccharide from the cell wall of Gram-negative bacteria to TLR4 on 
macrophages and microglia induces production of IL-1b and leads to sickness 
behaviour (87). Extracellular HSPs may therefore act as a DAMP on innate immune 
cells by activating their TLRs. Notably, we recently demonstrated that severe fatigue 
was associated with high plasma concentrations of HSP90α in patients with the 
autoimmune disease pSS and Crohn´s disease (88, 89). Generation of fatigue through 
cellular defense mechanisms could potentially shed light on the frequently reported 
lack of association between fatigue and disease activity in many studies.  
 
1.2.6 Fatigue cofactors 
In all studies performed there is a consistent association between depression and 
fatigue. Fatigue is one of the most commonly reported somatic complains indicating 
underlying depression, and is listed as one of the core symptoms in the clinical 
criteria for depression according to the 10-revision of the International Classification 
of Diseases (90, 91). There is an overlap in phenomenology and questionnaires for 
fatigue and depression often capture similar aspects, and therefore a circular 
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reasoning regarding causality may follow. Nevertheless, there are some distinctions. 
Whereas the patient with fatigue may keep their self-esteem and attribute their 
symptoms to physical limitations, depression often involve a negative view of self 
(92).  
 
Pain has been associated with fatigue in many chronic diseases (93, 94). Chronic pain 
negatively affects sleep, mood and quality of life (95). Traditionally, pain has been 
conceived as a somatic phenomenon, while fatigue and depression has been 
interpreted to be of more psychological origin. Pain is a subjective phenomenon that 
has been defined by the International Association for the Study of Pain as “an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage”.  Pain results from a 
combination of a peripheral stimuli and central processing. In chronic inflammatory 
diseases pain does not necessarily correlate with the degree of inflammation, and 
chronic pain may persist despite remission (96). Psoriasis is often accompanied by 
altered pain and thermal thresholds, also in non-involved skin tissue (97, 98). This 
could be caused by damage to nociceptors or peripheral nerves that can cause 
hypersensitivity to stimulus. Also, nociceptive sensory neurons express receptors for 
pro-inflammatory cytokines such as TNF-a, IL-1b, IL-6 and IL-17. Influence by 
these cytokines may directly decrease the excitation threshold of nociceptive neurons 
(99). Pain is a warning sign of proceeding tissue damage and as such it may induce a 
sickness behavior response.  
 
Chronic sleep deprivation is associated with fatigue. Sleep is a basic biological need 
for all complex organisms and serves an essential restorative function. Psoriasis 
patients often suffer from sleep disorders (100). There is no Norwegian word for 
fatigue and the term “tiredness and exhaustion” is therefore often used concurrently. 
This is in accordance with Piper´s expression “in contrast to tiredness, subjective 
fatigue is perceived as unusual, abnormal or excessive whole-body tiredness, 
disproportionate to or unrelated to activity or exertion” (101). Furthermore, 
disturbances in sleep are well known as a core symptom of depression.  
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In summary, co-factors such as pain, mood-, and sleep disorders may overlap and 
exacerbate each other and may increase the severity of fatigue. This complex 
interplay could potentially be explained by an overlap in biological pathways in the 
genesis of these manifestations.  
 
1.2.7 Treatment 
Up to date there are no specific effective fatigue treatment. There is substantial 
evidence for some beneficial effect of biological drugs in chronic inflammatory 
diseases (102). Furthermore, some evidence supports a beneficial effect of aerobic 
exercise on fatigue in a variety of underlying diseases (62).  
 
In the clinical approach to fatigue, treatment of the underlying condition/disease 
process may not be sufficient. Supportive management e.g. addressing treatable 
cofactors which could contribute to fatigue and help patients to develop techniques to 
better self-manage are generally recommended. Treatment of conditions which could 
potentiate the fatigue experience like anaemia, hypothyroidism and severe vitamin D 
deficiency may give small improvements in fatigue, which could improve QOL. 
Comorbidities like type II diabetes and cardiovascular disease could independently 
cause fatigue. Disrupted sleep due to e.g. obstructive sleep apnoea or any other cause 
of fragmented sleep like pain or pruritus should be sought and managed or referrals to 
appropriate services should be offered. Although mood disorders could be a 
consequence of, or a source to fatigue, patients suffering from emotional disturbances 
should be optimally treated. Nevertheless, the effect of antidepressants in treatment of 
depression associated with an underlying immune mediated disease is somewhat 
unclear (103). The most likely explanation for this is that peripheral immune 
activation in both human and other vertebras consistently induce sickness behavior in 
which the predominating features are consistent with major depression. This is highly 
suggestive of an interaction between inflammatory components and pathways 
involved in depression.  
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Further research into the molecular mechanisms for fatigue genesis could alter the 
understanding of psychological aspects of chronic inflammatory diseases, and lay 
foundation for further research into specific treatment options for this phenomenon.   
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2. Aims of the study 
• Write a review of the current knowledge of fatigue in psoriasis  
• Investigate the prevalence and severity of fatigue in psoriasis patients 
compared to healthy subjects 
• Investigate biomarkers of oxidative stress and fatigue in psoriasis patients 
• Explore the influence of selected cytokines on fatigue in psoriasis patients 
• Investigate HSP gene expression levels in psoriasis patient with high 
compared to low fatigue  




3. Subjects and methods  
3.1 Study design 
Paper I was a non-systematic review of fatigue in psoriasis, Papers II, III, IV and VI 
are based on case-control studies, and Paper V was a meta-analysis where we 
assessed the effect of biological drugs on fatigue in patients with psoriasis.  
3.2 Psoriasis patients 
A total of 120 patients were consecutively screened for potential participation based 
on referrals letters to the outpatient clinic at Department of Dermatology, Stavanger 
University Hospital. Three patients were recruited from the follow-up clinic. Thirty-
six patients were excluded due to not meeting the inclusion criteria (n=30), lack of 
healthy control subjects that matched patients for age and gender (n=5), or withdrawn 
consent (n=1). Thus 84 patients were included for study. Recruitment was from 
November 2012 to May 2015. Inclusion criteria were Norwegian-speaking people of 
Caucasian origin, with chronic plaque type psoriasis, age 18 - 80 years, Psoriasis 
Area Severity Index (PASI) score > 0. Exclusion criteria were other non-plaque 
forms of psoriasis, psoriatic arthritis, other systemic inflammatory disease, cancer, 
and uncorrected hyper- or hypothyroidism.  
3.3 Healthy subjects 
The 84 healthy control subjects were predominantly recruited from acquaintances of 
the patients and were matched by age (± 3years) and sex with the individual patients. 
They fulfilled the same inclusion and exclusion criteria as the patients, except for the 




3.4 Clinical examination and disease activity  
All subjects underwent a clinical examination by IMS. Demographic and clinical 
data, medical history, current medication and tobacco smoking were recorded. 
Psoriasis severity was measured by the Psoriasis Area and Severity Index (PASI), and 
skin-related quality of life by the Dermatology Life Quality Index (DLQI). PASI 
takes into account the extent and the appearance of the lesions. PASI scores range 
from 0 to 72 (104). Severity may be graded into the following subgroups; mild 
disease (PASI<7), moderate disease PASI 7-12 and severe disease PASI > 12 (105). 
In clinical practice severe psoriasis is commonly defined as PASI >10 (106). DLQI is 
a QoL instrument used in dermatology. It consists of 10 questions concerning the 
patients` perception of the different aspects of QoL over the last week. It includes 
aspects such as symptoms and feelings, daily activities, leisure, work or school, 
personal relationships and side-effects of treatment. Each item is scored on a 4-point 
scale: not at all/not relevant = 0, a little = 1, a lot = 2 and very much = 3. The 
individual scores are added to yield a total score ranging from 0-30; higher scores 
indicate greater impairment of QoL.  
3.5 Measures of fatigue 
Fatigue was evaluated by three different generic fatigue instruments. fVAS consists 
of a 100 mm line with vertical anchors in both ends, where 0 denotes “no fatigue” 
and 100 “worst possible fatigue”. A cut-off score of  ³ 50 was defined as clinically 
important fatigue (71). The SF-36 VS comprises four questions regarding fatigue. 
The subscale score yields a result ranging from 0 to 100, where lower scores 
represent more fatigue. Clinically important fatigue was defined by a cut off score of 
£ 35 (107). The Fatigue Severity Scale (FSS) includes nine statements regarding 
fatigue over the last two weeks. To each item the patient assigns a score from 1 
(completely disagree) to 7 (completely agree) which are summed and divided by nine 
to get a summary score. A cut off of 4 was applied to define clinically important 
fatigue (108).  
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3.6 Measures of pain and depression  
Pain was rated using the pain subscale of the SF-36. Two questions regarding the last 
four weeks intensity of pain, and if it has interfered with daily activities, comprise the 
subscale score. Higher scores indicate less pain (109).  
 
Depression was scored by the depression subscale of the Hospital Anxiety and 
Depression Scale (HADS-D) (110). The scale has seven items on depression of which 
all are answered from 0 to 3, and the responses are summed to obtain a depression 
score. A cut off of  ³ 8 has previously been used as cut off for depression (111). 
3.7 Laboratory analyses  
Blood was drawn by venous puncture in the morning after an overnight fast. Serum 
for routine laboratory analyses were separated from blood cells (centrifuged 7 min at 
2600×g at 22 °C) within 2 h and analyzed within 5 h after collection. Peripheral 
venous EDTA blood samples for research purposes were centrifuged (15 min at 
2500×g at 4 °C) within 30 min of sampling, and aliquots of plasma were stored at 
−80 °C until analysis. Furthermore, whole blood samples were collected from each 
patient into two PAXgene blood RNA tubes (Qiagen) per patient and kept for 2 h at 
room temperature, placed in a freezer at -20°C for 24 hours, and thereafter kept at -
80°C for storage.  
 
3.8 AOPP and MDA 
Advanced oxidation protein products (AOPP) is an unspecific measure of oxidized 
proteins that is generated by oxidative changes of amino acids. Di-tyrosine is a main 
contributor to AOPP, but AOPP also comprises other chromophores including 
carbonyl and pentosidine. Di-tyrosine is formed by dimerization of tyrosine generated 
as a result of activation of neutrophil granulocytes observed in inflammation. UV-
spectrometry is the current standard monitoring method for detection of AOPP. The 
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analysis is based on absorbance of light at 340 nm. The more light that has been 
absorbed at this wavelength, the higher estimated AOPP concentration (112).  
Malondialdehyde (MDA) is a relatively stable end-product of lipid peroxidation. It 
can be analyzed by different methods which vary in selectivity and sensitivity. In this 
study we used high-performance liquid chromatography (HPLC) connected to a 
fluorescence detector. MDA is a small molecule that occur in very low concentrations 
in biological samples. It does not fluoresce and its molar extinction coefficient for 
UV and visible light is very low. In order to improve the detection limit, 
derivatization is necessary. The most widely used derivatization reagent is 
thiobarituric acid (TBA). The reaction of MDA with TBA in an acidic environment 
leads to formation of a MDA-TBA2 complex that can be detected by visible 
spectrometry at wavelength 532nm or by fluorescence spectrometry at 
excitation/emission wavelengths 525/560nm. There are other compounds than MDA 
that can react with TBA, and they are often referred to as TBA-reacting substances 
(TBARS). To improve specificity for the MDA-TBA2 complex, it can be separated 
from other TBARS by HPLC before detection by visible or fluorescence 
spectrometry. The fluorescence detector improves the specificity compared to visible 
light spectrophotometry by only detecting chromophores with fluorescent abilities 
(113). 
 
3.9 Immunologial methods for cytokine analyses 
Immunological methods are based on the interaction between antigens and 
antibodies, but varies in techniques for immobilizing a capture antibody and 
detection-system for quantification of the antigen. For analyses of IL-1RII plasma 
concentrations, we utilized sandwich enzyme-linked immunosorbent assay (ELISA). 
Plasma concentrations of IL-1β, IL-1Ra, IL-6 and IL-10 were measured by 
electrochemiluminescence (ECL) based Meso Scale Discovery (MSD) assay.  
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3.9.1 Sandwich ELISA 
Sandwich ELISA is a frequently used method for quantitative detection of cytokines 
that utilizes two specific antibodies to form a sandwich with the cytokine of interest. 
Briefly, a capture antibody with specificity for the cytokine is immobilized on the 
microtiter wells. Biological samples and standard samples (containing a known 
concentration of the cytokine) is added. The cytokine binds with the capture antibody. 
A detection antibody linked with horseradish peroxidase (HRP) is added to form a 
sandwich with the captured cytokine. A colourless tetramethylbenzidine (TMB) 
solution is added. TMB is oxidised by HRP to yield the blue TMB diimine which turn 
yellow after acidification (Figure 2). The intensity of the color is proportional to the 
amount of cytokine in the sample. Finally, the absorption is measured with a 
spectrophotometer at 450 nm. The unknown plasma concentration of cytokine in the 
samples is calculated by use of calibration curve made from the standard samples 
containing known concentration of the cytokine (114).  
 
3.9.2 ECL assay  
Specific capture antibodies for IL-1β, IL-1Ra, IL-6 and IL-10 are immobilized at 
corresponding spots on microplate wells with an electric surface. The capture 
antibodies bind to the corresponding cytokine when the samples are added. The 
bounded cytokines are then detected by a secondary antibody that is conjugated to a 
SULFO-TAGTM (MSD). Upon electrochemical stimulation initiated at the electrode 
surfaces a redox reaction commences, and the SULFO-TAGTM emits light at 620nm. 
By measuring the intensity of the emitted light one can quantify the concentration of 












Figure 2. Illustration of ELISA and ECL principles.  
In both assays specific capture antibodies are fixed to the well bottom of the assays. The ELISA 
method we used can only detect one cytokine at the time, MSD can detect up to 10 different 
cytokines. The detection or secondary antibodies have different tags attached. In ELISA the tag is an 
enzyme (e.g. horseradish peroxidase (HRP)) that create a colorimetric reaction when exposed to a 
chemical substrate (e.g. tetramethybenzidine). In MSD, however, the detection antibody is attached 




All samples were run in triplicates. The intra-assay variation, expressed as coefficient 
of variations (CV) were < 15%. The inter-assay variation was assessed by measuring 
the same control on each plate (n=10 plates for cytokines measured on ECL, and n=9 
plates for ELISA) and were 29.5% (IL-1β), 11.6% (IL-1Ra), 10.8% (IL-1RII), 29.1% 
(IL-6) and 12.3% (IL-10). This is in agreement with variations given from the assay 
manufacturer for IL-1Ra, IL-1RII and IL-6, but slightly higher for IL-1β and IL-10. 
These deviations can be explained by low concentrations of the cytokines in the 
internal control samples. In the low concentration end of the standard curve the 
measurements will often have greater variation thus higher CV. The 
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concentrations of our internal controls were comparable to samples from the study 
population, unlike the concentrations used by the manufacturer to assess CV.  
3.10 HSP gene expression studies 
Gene expression is a term meaning transcription from deoxyribonucleic acid (DNA) 
to ribonucleic acid (RNA) into protein. RNA is a highly regulated, single stranded 
molecule. It is not possible to sequence RNA directly. However, we can sequence 
RNA indirectly by reverse transcriptase from RNA to complementary DNA (cDNA). 
The cDNA molecule is more stable than RNA and can be amplified by polymerase 
chain reaction (PCR). The PCR process is based on a series of temperature changes 
(cycles), which are repeated 40 to 45 times. Each cycle consists of three steps, DNA 
denaturation (95°C), binding of primers (annealing) (55°C) and extension of single-
stranded DNA molecules (72°C). The amplified cDNA will give an estimate of the 
expression level of the RNA.  
3.10.1 RNA-sequencing (RNA-seq).   
The transcriptome is the sum of all RNA transcripts in a cell or sample, i.e. it captures 
a snapshot of the total transcripts present at a given timepoint. There are different 
methods that can be used to generate transcriptome data. RNA-seq uses high-
throughput sequencing to quantitate transcripts present in an RNA extract (115). 
High-throughput sequencing is the current dominant transcriptomics technique. This 
technique gives information on which genes are active and the magnitude of 
transcription.  
The process involves three main steps; prepare a sequencing library, sequencing and 
data analyses. The total RNA is isolated from a sample and messenger RNA (mRNA) 
is selected for downstream analyses. As the sequencing machine can only sequence 
short (200-300 bp) fragments, mRNA is broken into small fragments which are 
converted into double stranded cDNA. 
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Sequencing adaptors are added that allow the sequencing machine to recognize the 
fragments to create a library for sequencing. Sequencing of these fragments involves 
generation of “read pairs” with two reads in either end of each fragment (separated by 
a fixed distance). The library is thereafter polymerase chain reaction (PCR) amplified 
to enable enough reads for measurement. Only the fragments with sequencing 
adapters are amplified. 
The read pairs will then be aligned to the reference genome and the number of reads 
per gene counted. The number of RNA molecules that came from a specific gene 
should correspond directly to how many reads mapped to that gene. However, longer 
genes will have more reads. Therefore, the reads need to be normalized by gene 
length to determine expression. Furthermore, the number of reads that was sequenced 
need to be normalized, i.e. how deep was the sequencing. Instead of raw read counts, 
expression values are generally given in terms of FPKM. This unit stands for 
fragments (fragments are read pairs) per kilobase of gene (per length of the gene in 
units of kilobase) per million mapped reads (how many reads per million reads) 
(116). This normalized value will allow comparing one gene to another gene within 
the same sample because we have normalized by gene length. Furthermore, one can 
compare across different samples because we have also normalized by sequencing 
depth (i.e. library sizes; the total number of mapped reads). 
We used principal component analysis (PCA) to visualize potential patterns in the 
selected HSP dataset. In the resulting PCA plot there was a clear tendency that the 
patients clustered in groups based on reported fatigue levels along the first principal 
component. To make the clusters more visible in the plots, the symbols were color-
coded according to high or low fatigue. Based on the corresponding loading plot a set 
of candidate HSP genes, strongly congregating to the first principal component, were 
selected for re-evaluation by reverse-transcription real-time quantitative polymerase 




RT-qPCR is a widely used method for gene expression analyses. While the RNAseq 
is a hypothesis-free approach that does not require prior knowledge of sequence 
information, RT-qPCR can only be used for analyses of known sequences (117).  
The RT-qPCR system detects the products at the extension step of each PCR cycle by 
using a non-specific fluorescent dye, SYBR Green, which binds to double-stranded 
DNA. An increase in PCR product will cause increased fluorescence intensity (118). 
The quantitation of PCR product is relatively compared to an internal reference gene. 
Reference genes are genes that are expressed at a constant level in different tissues of 
an organism. Reference genes are used as internal reaction control to normalize 
mRNA levels between different samples in order to allow for a more optimal 
comparison of mRNA transcription levels.  
 
At the end of an RT-qPCR process, the system allows to analyze several aspects of 
the procedure e.g. the melting curve analyses are used to verify single PCR products 
and absence/presence of primer dimers.  
 
Genes were measured in triplicates as a necessary means to control for PCR 




Figure 3. Schematic presentation of RNAseq and RT-qPCR.  
After RNA extraction mRNAs are isolated from other varieties of RNA based on binding of their 
poly(A) tail to complementary oligo-dT chains attached to magnetic beads. The mRNA is used to 
make the second strand of cDNA. This double stranded cDNA is enzymatically fragmented. 
Adaptors attached to the ends of these molecules allow the sequencing to recognize the fragments. 
Only fragments with sequencing adaptors are amplified. Finally, sequences are mapped to a reference 
genome for quantitation of expression levels. The more reads the higher expression level of the 
specific gene. In RT-qPCR, specific primers are added to the cDNA. SYBR green binds to all 
double‐stranded DNA and emits a fluorescent signal. In its unbound state, SYBR green does not 
fluoresce. Template amplification is measured in each cycle by the corresponding increase in 
fluorescence 
 
3.11 Ethical considerations 
The study was approved by the Regional Committee for Medical Research in Norway 
(REK vest 2010/1455) and conducted in accordance with the Declaration of Helsinki. 
Prior to their scheduled outpatient appointment, information about the study was 
posted to the participating patients. Written informed consent were obtained from all 
included participants.  
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3.12 Statistics  
Unless otherwise stated, the statistical analyses were performed using the most recent 
IBM SPSS Statistics version available. We generally used two-sided tests with level 
of significance P < 0.05, and point estimates are supplied with 95% confidence 
intervals (CI). 
 
Descriptive statistics of continuous variables were presented as mean and standard 
deviation (SD) if symmetrically distributed or median and interquartile range (IQR) if 
skewed. Distributions were assessed by visual inspection of histograms and QQ-plots. 
Most continuous data were not normally distributed, and for the purpose of simplicity 
median and IQR were sometimes preferred for all variables. Comparison of 
continuous variables between groups was similarly performed using respectively the 
independent samples t-test or the Mann-Whitney U test. Categorical variables were 
presented with counts and percentages. For comparison of categorical variables 
between groups, the Chi-square test or the Fisher´s exact test was used. In Paper II, 
the Wilcoxon paired sample test was used to test for differences in paired continuous 
data, and McNemar´s test was used for pair-wise categorical data.  
 
Except for Paper VI, simple or multiple linear regression analyses were used to 
estimate associations between continuous dependent variables. Dependent variables 
which were not normally distributed were transformed using the natural logarithm 
before employed in regression analyses. Overall model fit was assessed by R2. For 
each individual independent variable, estimated effect (beta) and 95% CI were 
determined, as well as the P value for Wald test of hypothesis of no effect.  Change in 
R2 (Δ R2) was used to assess the contribution of the individual variables in the model. 
Variables with a P < 0.25 in univariable analyses were included in multivariable 
linear regression modelling. Both stepwise forward and backward selection 
procedures were performed to identify variables that should be included in the final 
model. In Paper VI logistic regression analyses were used for analyses of associations 
between fatigue as a dichotomous variable and HSP gene expression levels. The 
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estimated odds ratios (ORs) and 95% confidence intervals (CIs) and p-values from 
Wald tests of hypotheses of no association were determined. Unadjusted odds ratios 
(OR)s, as well as ORs adjusted for clinical variables were presented.  
 
For Paper V we conducted meta-analysis using Stata v. 15.1. The standardised mean 
difference (SMD) in change from baseline in fatigue scores between biologic and 
placebo therapy was used as the primary outcome measure. Random effects and fixed 
effects meta-analyses was performed using the DerSimonian and Laird and reverse-
variance methods, respectively (119) . The consistency between studies was 
measured by I2 (119) and potential publication bias was assessed using a funnel plot. 
 
Statistician and co-author Ingvild Dalen was the statistical advisor. Further details of 




4. Summary of results 
4.1 Paper I:  
This is a non-systematic review article related to fatigue in psoriasis. The concept of 
sickness behaviour was used as an explanatory model for fatigue. The literature 
search included articles that described hypotheses regarding immunological 
mechanisms for fatigue. Available evidence for presence of fatigue in psoriasis was 
explored. Knowledge gaps on this topic in psoriasis research were identified such as 
the prevalence and severity of fatigue, the pathophysiological mechanisms as well as 
the evidence on the effects of pharmacological therapies for fatigue in psoriasis 
patients.  
4.2 Paper II: 
In this study we investigated the prevalence and severity of fatigue in 84 patients with 
plaque psoriasis compared with 84 age- and gender-matched healthy subjects, and 
explored the potential influence of essential clinical and demographic factors on 
fatigue among the patients. Severity of fatigue was assessed using three different 
generic and well-validated fatigue instruments: fVAS, FSS and the SF-36 VS .  
 
We found that in the patients and healthy subjects the median fVAS scores were 51 
and 11, FSS scores were 4 and 1.6, and SF-36 VS scores were 43 and 73, 
respectively. Among patients versus healthy subjects, the rates of clinically important 
fatigue were 51% vs 4% (fVAS), 52% vs 4% (FSS), and 42% vs 2% (SF-36) (all P < 
0,001). There was no association between fatigue and psoriasis disease activity 
(PASI), while smoking, pain and depression significantly influenced the severity of 
fatigue.  
 
In conclusion, nearly 50% of psoriasis patients suffer from clinically important 
fatigue, a considerable higher prevalence than among the healthy subjects. 
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4.3 Paper III 
Many studies claim that oxidative stress is involved in the pathophysiology of 
psoriasis, although typically, systemic inflammation is very low grade. In this study 
we compared plasma concentrations of AOPP and MDA between 84 patients with 
psoriasis and 84 age- and gender-matched healthy subjects. We also explored whether 
AOPP or MDA were associated with clinical characteristics of patients including 
fatigue. Plasma AOPP was measured with spectrometry and MDA concentrations 
were measured with HPLC connected to a fluorescence detector.  
 
Median (interquartile range, IQR) AOPP concentrations were 66 µmol/l (IQR: 
54−102) in patients and 69 µmol/l (IQR: 55−87) in healthy subjects (P = 0.75). 
Median plasma MDA concentrations were significantly lower in patients than in 
healthy subjects (0.68 µM, IQR: 0.54−0.85 vs. 0.76 µM, IQR: 0.60−0.97; P = 0.03). 
Higher AOPP concentrations were associated with male gender, high body mass 
index, and high hemoglobin values. Likewise, higher MDA concentrations were 
associated with advanced age and male gender. No significant associations with 
disease severity nor with fatigue were revealed.  
 
In conclusion, oxidative stress was not increased in patients with psoriasis compared 
to healthy subjects. Several non-disease related factors might influence the measured 
levels of AOPP and MDA. These issues should be considered when interpreting 
results regarding these biomarkers in patients with psoriasis.  
4.4 Paper IV 
It has been suggested that pro-inflammatory cytokines play a causative role in 
fatigue. With reference to this we conducted a controlled study and explored the 
plasma levels of select cytokines in 84 patients with psoriasis and 84 age- and gender 
matched healthy subjects and compared them with fatigue severity and other clinical 
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factors. IL-1RII was measured by ELISA and IL-1β, IL-1Ra, IL-6, and IL-10 by 
ECL.  
 
IL-1Ra and IL-6 concentrations were significantly higher in patients than healthy 
subjects. (203 pg/mL, IQR: 150 – 274 vs. 166 pg/mL, IQR: 128 – 212; P = 0.008 and 
0.82 pg/mL, IQR: 0.18 - 1.40 vs. 0.50 pg/mL, IQR: 0.18 - 0.91; P = 0.009, 
respectively). Higher levels of IL-1Ra and IL-6 were associated with increased body 
mass index. Cytokine concentrations and disease activity did not influence fatigue.  
 
In conclusion, these findings do not support an association between fatigue and blood 
concentrations of selected pro- and anti-inflammatory cytokines. Furthermore, the 
cytokine plasma concentrations are predominantly influenced by higher BMI, and not 
disease severity.   
4.5 Paper V 
Biologic therapy is effective in treating psoriasis skin symptoms. In this study we 
undertook a PubMed search and performed a meta-analysis of randomized controlled 
trials on the effect on fatigue from biological therapies used for psoriasis vulgaris. 
Eight trials were included. We found a consistent small to moderate effect of 
biological drugs on fatigue compared to placebo, with a standardized mean difference 
of -0.40 (95% CI, -0.46 to -0.34). The effect was independent of the type of 
biological drug used.  
 
4.6 Paper VI 
Recent evidence suggests a role for HSPs in generation of fatigue in chronic 
inflammatory diseases. Therefore, we investigated the expression levels of selected 
HSP genes in peripheral blood mononuclear cells (PBMC) of psoriasis patients with 
high and low fatigue. Total mRNAs from PBMC of 10 patients with high fatigue 
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scores (fVAS 63-92) and 10 with low fatigue (fVAS 0-31) were analysed by RNA-
seq. Principal component analyses (PCA) was utilized to screen for differentially 
expressed HSP genes between patients with high and low fatigue. RT- qPCR was 
thereafter applied to confirm the expression profiling of 4 selected candidate HSP 
genes from PBMCs of 20 patients with high (fVAS 64-97) and 20 patients with low 
(fVAS 0-25) fatigue scores.   
 
RNA-seq analyses demonstrated that HSPB11, HSPBAP1, HSPA14 were upregulated 
in patients with high fatigue and HSPA9P1, HSP90B1, HSP90AB1 downregulated. 
The expression levels of these upregulated and downregulated HSP genes contributed 
most to the separation of patients with high and low in an unsupervised PCA.   
 
RT-qPCR levels of HSPB11 and HSP90B1 displayed a similar mode as the RNA-seq 
results. Patients with high fatigue scores had higher expression levels of HSPB11 and 
lower expression levels of HSP90B1 compared to patients with low fatigue. Psoriasis 
disease activity did not influence the expression levels of any HSP genes in our study.  
 
These results indicate a role for HSP signaling in fatigue in patients with psoriasis. 
 52
5. Discussion  
Fatigue is a common phenomenon across inflammatory conditions, but is somewhat 
underrecognized in dermatological contexts. There was a knowledge gap regarding 
fatigue in psoriasis and the overall aim of this thesis was therefore to investigate and 
describe fatigue in psoriasis patients and compare with an age- and gender matched 
control group consisting of healthy subjects. Furthermore, the project aimed to 
uncover biological mechanisms that signal fatigue to the brain.  
5.1 Main findings  
Initially we performed a non-systematic review of selected articles on fatigue and 
psoriasis. A lack of genuine investigations on fatigue prevalence and severity in 
patients with psoriasis was identified. 
 
The case-controlled study demonstrated that approximately 50% of psoriasis patients 
reported clinical important fatigue. This figure was much higher than in healthy 
subjects. Fatigue severity was associated with depression, pain and smoking, but with 
not disease activity. 
 
Oxidative stress, assessed by plasma protein oxidation and lipid peroxidation, was not 
increased in psoriasis patients compared to healthy individuals. In addition, we could 
not reveal any association between measures of oxidative stress and psoriasis disease 
activity nor with fatigue.  
 
There were no associations between plasma concentrations of selected cytokines and 
fatigue. The cytokine plasma concentrations in psoriasis patients were predominantly 
influenced by higher BMI, and not disease severity.  
 
Biological drugs have a small to moderate effect on fatigue in psoriasis patients. It 
was not identified any subgroup effects among the different types of biological drugs 
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in the study. Intriguingly, the majority of reported clinical trials on biological drugs 
for treatment of psoriasis vulgaris did not include fatigue measures as either primary 
or secondary endpoints.  
 
There was an association between expression levels of some of the selected HSPs 
genes and fatigue severity in psoriasis patients. HSP gene expression was influenced 
by BMI, but not disease activity.   
 
5.2 Discussion of main results  
5.2.1 Fatigue severity and associated factors in psoriasis  
The prevalence of clinically important fatigue in psoriasis patients that we revealed is 
in line with studies in other inflammatory diseases. In a controlled study of newly 
diagnosed and untreated patients with inflammatory bowel disease; 48% of patients 
with Crohn's disease and 42% with ulcerative colitis reported fatigue (64).  
 
A lower mood state occurs more often in patients with psoriasis than in the normal 
population (47) and was in our study strongly associated with fatigue. “Loss of 
energy” is one of the criteria for a severe depressive episode (90). The association 
between fatigue and depressive symptoms may therefore be partly due to overlapping 
symptomatology. A leading hypothesis is that fatigue and depression both are parts of 
the sickness behavior response. This is a well-preserved defence mechanism in 
humans and animals with the advantage of improving survival during conditions with 
infections and bodily damage. The behaviour encompasses several phenomena, such 
as reduced physical activity, fatigue, depression, social restraint, and loss of thirst and 
hunger. Features of sickness behavior are likely to share common molecular 
signalling pathways (120).  
 
The association between pain and fatigue is well documented, and was also 
confirmed in our study. Nociception involves a central nervous response to painful 
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stimuli in which the signals are transmitted from the periphery to the cerebral cortex 
and perceived as pain by the individual. The perception of pain leads to behavioral 
changes displayed as features of sickness behaviour. It is therefore to be expected that 
these phenomena are tightly correlated.  
 
Smokers reported more fatigue than non-smokers. The association between smoking 
and fatigue was not statistically significant when smoking was kept as a continuous 
variable, i.e. numbers of cigarettes daily. The interpretation of this is not perfectly 
clear. In the cohort there was a relatively low number of smokers and it would have 
been interesting to study this further in a larger data set. Whether smoking per se is 
associated with fatigue or if the amount of smoking is related to more severe fatigue 
remains unclarified. Nicotine may have antidepressant effects due to stimulation of 
release of neurotransmitters including serotonin, dopamine and norepinephrine (121). 
Although it has been demonstrated that nicotine reduces fatigue, little research has 
investigated this effect further (122). We hypothesize that smoking probably 
identifies a subgroup of people in which psychosocial factors may influence fatigue.  
 
 
5.2.2 Endproducts of oxidative stress do not influence fatigue  
Some studies have revealed increased oxidative stress in psoriasis, and hypothesize a 
role in  pathogenesis of psoriasis (123). Indicators of oxidative stress have also been 
linked to increased disease severity (124). The results in our study were therefore 
somewhat unexpected. A possible reason for the conflicting results is that the 
majority of our patients had predominantly mild psoriasis, which reduces the 
possibility to identify differences between the groups. Our study provided evidence to 
suggest that there are several contributing factors which are important to adjust for in 
analyses of AOPP and MDA including BMI, the latter closely related to disease 
severity (42). An association between chronic fatigue and measures of oxidative 
stress has been demonstrated in chronic fatigue syndrome / myalgic 
encephalomyelitis (CFS/ME) and in SLE (125, 126). The lack of association between 
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measures of end-products of oxidative stress and fatigue in our study does not 
necessarily mean that oxidative stress is not involved in the generation of fatigue. A 
possible explanation might be that the analytical methods are not accurate enough to 
detect minor and physiological increased amounts of ROS in this condition. Also, 
slight elevation of the markers in the periphery may not necessarily lead to activation 
of fatigue signaling pathways to the brain.  
 
5.2.3 Plasma cytokine concentrations do not influence fatigue  
Our results indicate that peripherally produced cytokines do not directly influence the 
severity of fatigue in psoriasis patients with mild disease. However, in inflammatory 
conditions IL-1β pass through the BBB into the brain and activate neuronal cells and 
microglia cells to produce IL-1β that binds to specific IL-1 receptors on nearby 
cerebral neurons. Intrathecal cytokine concentrations may therefore be more 
applicable when studying the influence of cytokines on fatigue.  
 
The fact that fatigue is not associated with plasma concentrations of selected 
cytokines could partly explain the frequently reported lack of association between 
fatigue and disease severity (70). This may direct future research towards other 
pathways. Such alternative pathways could be cellular stress responses. However, a 
larger study group that included patients with more severe psoriasis and presumably 
higher cytokine concentrations would have been necessary to robustly exclude a 
correlation between blood cytokine levels and fatigue in psoriasis patients.  
 
It would have been useful to measure potential influence of other relevant cytokines, 
such as TNF-a, but this was beyond our time and resources when the analyses were 
conducted. Future research on the relation between the peripheral inflammation and 




In the present patient cohort, the concentrations of IL-1Ra and IL-6 were 
predominantly influenced by higher BMI, and not disease severity. So-called 
adipokines i.e. cytokines released by adipose tissue play an important contributing 
role to the low-grade systemic inflammation seen in this patient group (127). Our 
finding highlights the importance of BMI as a confounder between psoriasis per se 
and systemic inflammatory markers.  
 
5.2.4 Effect of biological treatment on fatigue in psoriasis  
The effect of biological interventions on fatigue in psoriasis had not previously been 
systematically reviewed. We found the effect of biological treatment to be mild to 
moderate, and could not identify any subgroup effects of different types of biological 
drugs. Among the identified relevant trials, fatigue was only at best reported as 
secondary outcomes. This reflects the relatively little attention that has been given to 
the phenomenon in dermatology. The scores were usually measured quite early in the 
trial periods (i.e. at, or before 16 weeks), and the long-term effect on fatigue is yet to 
be established. Our findings are in agreement with studies in other chronic 
inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease 
(102, 128). 
 
5.2.5 Altered HSP gene expression may be related to fatigue  
Our study demonstrated that HSPs gene expression pattern profiles in PBMC differed 
between patients with high and low fatigue. In psoriasis patients with high fatigue the 
expression levels were increased for of HSPB11 and decreased for HSP90B1 
compared to patients with less fatigue. These findings were consistent in the RNA-
seq and RT-qPCR mRNA analyses. 
 
In the light of HSPs' important roles for protecting cellular life it is possible that 
mechanisms that induce fatigue through HSP signalling have evolved during 
evolution. Our study was exploratory with small number of patients and needs to be 
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confirmed in future studies with larger sample size. Furthermore, the gene expression 
profiles must be confirmed on protein levels before a more valid conclusion can be 
drawn. However, to the best of our knowledge, this is the first time a study has 
demonstrated findings suggestive of genetic mechanisms as contributors of fatigue in 
psoriasis patients. This opens the possibility to future studies in the same area.  
 
5.3 Methodological considerations 
5.3.1 Study design: 
The patient cohorts in Papers II, III and IV was recruited from our local hospital 
catchment area and presumed representative for the average patients receiving 
treatment at hospital level in this health trust. A relatively large sample size has been 
investigated in the studies reported in Papers II, III and IV. It can therefore be 
assumed that the results can be generalised to patients with the same diagnosis in our 
hospital region. To avoid bias towards different levels of education and social 
adjustments, the healthy subjects were mainly recruited from acquaintances and 
friends of the patients. Furthermore, the healthy subjects were age- and gender 
matched with the patients.  
 
We used validated, and internationally widely accepted, generic fatigue measuring 
instruments. This permits access to valid data that can be used to compare with non-
dermatological diseases and healthy control subjects.  
 
Many biomarkers are susceptible to degradation or other changes in the preanalytical 
processing of samples, as well as influenced by temperature and duration of storage. 
Blood was drawn at fasting state with equal pre-processing steps. All samples were 
subsequently stored at one biobank at -80◦C and processed at one site under similar 
conditions by the same personnel. None of the samples were frozen and thawed more 
than once before analyses.  
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There are some shortcomings. The cross-sectional design prevents any conclusion 
about causality. Only associations can be described in an observational study like 
this. One important weakness in our study is the relatively low disease activity. This 
might have influenced some of the associations or lack of these. Low number of 
patients with severe disease limits the statistical power of comparisons between 
patients with various degree of disease severity. Lack of statistical significance must 
therefore be interpreted with caution. However, despite this limitation, it was revealed 
that fatigue is a prevalent and severe phenomenon even in the subgroup of psoriasis 
patients with predominantly low disease activity.  
 
5.3.2 Measures of oxidative stress  
There are several biomarkers for oxidative stress. In Paper III, two frequently used 
biomarkers of oxidative stress were utilized; AOPP and MDA, which assess the end 
result of two different oxidation processes. We developed, modified and validated 
methods for MDA and AOPP and used them in several different patient cohorts, 
thereby minimizing the errors introducing new markers. One limitation is that we did 
not measure other indicators of oxidative stress e.g. biomarkers of the antioxidant 
defence system, nor DNA oxidations. A major obstacle in the interpretation of results 
regarding biomarkers of oxidative stress, is the lack of international standards for 
analyses and quality assurance of the data. As a result, it is difficult to compare 
studies from different laboratories.  
 
It is puzzling that AOPP and MDA have been known as measures for oxidative stress 
for more than 20 and 40 years, respectively. Yet, one cannot use a measured value as 
a meaningful diagnostic, prognostic or predictive tool. Established general reference 
values are lacking. Therefore, each study must include a reference group.  
 
Increased oxidative stress seems to be associated with several diseases and 
conditions. In addition, redox reactions also play an important part of the normal 
metabolism. Given the complexity of these processes, the meaning of oxidative stress 
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biomarkers in specific diseases remain somewhat uncertain even with available 
standardized monitoring methods.  
 
AOPP is measured by UV-spectrometry which is a fast, simple and inexpensive 
method to determine the concentration of an analyte in a solution. AOPP was first 
described by Witko-Sarsat et al. in 1996 (112). The method and modified versions of 
it have been used in a large number of reports and studies thereafter. Absorbance at 
340 nm is not specific for AOPP since other compounds, such as hemoglobin also 
absorb at 340 nm. Furthermore, a major disadvantage is that it can be disturbed 
through interference of turbidity in the samples, often due to lipemic plasma. Thus, 
this method allows only a screening of the degree of oxidative stress and is not a very 
specific measure of oxidized proteins. During the last years we have optimized the 
method to reduce spectrophotometric interference from lipids and hemolysis that 
cause falsely elevated optical densities.  
 
The majority of studies on oxidative stress in psoriasis patients have investigated the 
levels of lipid peroxidation products. In contrast to our findings, higher 
concentrations in patients compared to healthy subjects are commonly revealed (123). 
A reason for this could be the choice of analytical method. MDA levels can be 
determined by different methods which vary in selectivity and sensitivity. Simple 
UV-spectrophotometric methods without chromatographic separation have often been 
used, but few publications mention the weaknesses of this method. HPLC connected 
to a fluorescence detector is a more specific method that separates MDA from other 
interfering compounds. This might be of particular importance in psoriasis patients 
who have a propensity to hypertriglyceridemia, a phenomenon possibly associated 
with disease severity.  
 
5.3.3 Cytokine analyses  
Immunological analytical methods based on specific binding between antigens and 
antibodies were utilized for cytokine measurements. There are several techniques 
available, including, but not limited to, ELISA and ECL.  
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ELISA is a frequently used method for cytokine analyses. However, the method we 
used is limited by its ability to measure only one cytokine at a time and is therefore 
time consuming and costly. No commercial MSD multiplex kit for IL-1RII was 
available at the time of our study, and ELISA was utilized for its quantification.  
 
MSD is a multiplex assay that can simultaneously measure up to 10 cytokines from a 
single sample, and plasma concentrations of IL-1β, IL-1Ra, IL-6 and IL-10 were 
quantified by this method.  Multiple excitation cycles of each SULFO-TAGTM (i.e. 
each cytokine) enhance the emitted light and thus improves the sensitivity and 
dynamic range compared to ELISA 
 
Cytokines are not routinely measured in clinical practice although frequently used in 
research. This is partly due to challenges associated with rapid degradation and lack 
of established reference values for these compounds. 
 
It has been demonstrated that cytokines should be analysed in immediately cooled 
and centrifuged EDTA or citrate blood to avoid release of cytokines from blood cells 
after sampling. The cytokine levels are lower and more stable in plasma than in 
serum, suggesting that coagulation factors and thrombin present in serum enhance 
cytokine release from leukocytes (129).  
 
Psoriasis is generally associated with a low level of systemic inflammation and some 
cytokines are not measurable or found in very low- level similar to healthy subjects.  
In the present study, the concentrations of IL1β, IL-6 and IL10 were below the lower 
limit of detection (LLOD) in a high percentage of the patient plasma samples. LLOD 
of a method is defined as the lowest concentration that can be distinguished from the 
absence of the cytokine (a blank value). An important consideration in the 
interpretation of the results is that the values close to LLOD are usually less accurate 
and precise. There are different ways of approaching this problem. One method is to 
ignore data with measurements lower than LLOD, however omission of data below 
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LLOD is generally not recommended to avoid overestimation of mean concentration. 
Although the values are low, they may strongly impact the distribution of the data. A 
widely accepted used substitution method is by LLOD/√2 which was used in our 
study.    
The immunoassay analyses for detecting cytokines were conducted by experienced 
laboratory personnel.  
 
5.3.4 HSP gene expression  
RT-qPCR is a much used technique to measure cDNA and genomic DNA levels. The 
primary disadvantage of the SYBR Green dye detection of PCR products is that it is 
not sequence specific (118). The SYBR green dye binds to any double stranded DNA 
and may therefore generate false positive signals. This was overcome in our study by 
using highly specific primers that binds specifically to the gene or sequence of 
interest. Furthermore, the primer specificity was ensured by melting curve analysis. 
Melting curve analysis is an assessment of the dissociation characteristics of double 
stranded DNA during heating. SYBR Green only fluoresces when it is bound to 
double-stranded DNA.  
The temperature at which the two DNA strands is broken depends on their length thus 
a unique melting curve of the changing rate of fluorescence versus temperature will 
be produced for each specific double-stranded DNA fragment. If more than one DNA 
fragment is produced during the qPCR reaction, this will be reflected in the melting 
curve analysis.  
 
5.3.5 Systematic review 
Multiple databases are generally recommended when searching for relevant 
referenced in systematic reviews. A combination of Embase, MEDLINE, Web of 
Science Core Collection and Google Scholar has been shown to be the most optimal 
search strategy for systematic reviews (130). Due to time constraint the literature 
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search for in paper V was performed in PubMed only. PubMed began as an online 
version of MEDLINE index more than twenty years ago, but today also include 
PubMed Central (PMC). One can therefore risk that non-indexed articles are listed in 
PubMed as this is a back door from PMC.  
 
Given the nature of the studies (randomised controlled trials of biological drugs for 
psoriasis) we found it overly likely that any study covered in the analyses would be 
indexed in MEDLINE or PMC. The InCite Journal Citation Reports, which is the 
trusted and most widely used publication to identify relevant information on the 
impact of an academic journal based on citation metrics, lists a total of 68 journals in 
the field of dermatology. A search through these revealed that only four were not 
indexed for in MEDLINE or PMC. In our opinion all the relevant influential 
randomised controlled trials of approved biological drugs for psoriasis at the time of 
data collection were listed in PubMed and therefore this was an adequate source for 




6. Conclusions and future perspectives  
The results of the studies included in this thesis gives information of an overlooked 
aspect of psoriasis. We identified that clinically important fatigue is common among 
patients. Fatigue was strongly associated with pain and depression. This thesis also 
aimed to increase the understanding of biological mechanisms for fatigue in the 
context of sickness behavior. Although, several studies have indicated activation of 
the innate immune system, especially IL- Ib, as important fatigue generating 
mechanisms, we could not reveal a relation between blood circulating cytokines and 
fatigue nor between measures of oxidative stress and fatigue. A plausible explanation 
is that fatigue is not influenced by the peripheral inflammatory profile and that 
signalling molecules in low concentrations in blood do not reach the brain through 
BBB. Another hypothesis is that the complex behavioral aspect of chronic 
inflammation has its biological fundament in protective mechanisms against 
inflammation like the heat shock response. Our study is the first to reveal altered 
expression of selected HSP genes between psoriasis patients with high and low 
fatigue. Furthermore, we demonstrated a low to moderate effect of anti-inflammatory 
biological drugs used for treatment of psoriasis on fatigue. 
Our studies can inspire future studies on fatigue in psoriasis which in turn may lay 
foundation for further research into therapeutic possibilities of this phenomenon. 
Challenges for these studies would be to design larger cohorts and to include patients 
with more severe psoriasis disease. Additionally, it is desirable to confirm alteration 
of gene expressions related to fatigue on a protein level and especially perform CSF 
analyses of candidate molecules. Our study was cross-sectional and follow up 
changes were not evaluated. Longitudinal studies could potentially follow changes in 
severity of fatigue, therapeutic response to anti-inflammatory and 
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8.1 Fatigue Visual Analog Scale 
 
 
Tretthet og utmattelse 
 
 
Dette spørreskjemaet spør om hvordan du har opplevd følelse av tretthet og utmattelse den 
siste uken.  
 
Linjen nedenfor er et mål på hvor mye tretthet og utmattelse du har opplevd den siste uken. 
Helt til venstre på linjen er “ingen problemer med tretthet og utmattelse” og helt til høyre er “så 
mye tretthet og utmattelse som det er mulig å ha”.  
 
Vi ber deg sette et merke med blyant eller penn på linjen nedenfor som passer med den følelse 
































Så mye tretthet 
og utmattelse 
som det er 
mulig å ha 
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8.2 Fatigue Severity Scale  
 
Skala for tretthet og utmattelse (fatigue severity scale) 
 
Dette skjemaet utfylles av forsøkspersonen under veiledning av intevjuer. Til høyre for hver påstand 
skal det skrives et tall. Velg et tall fra 1 til 7, der 1 betyr helt uenig med påstanden og 7 betyr helt 
enig med påstanden.    
___________________________________________________________________________ 
 
               Tall 
1. Mitt pågangsmot blir dårligere når jeg er utmattet    ____ 
 
 
2. Jeg blir fort utmattet ved anstrengelser     ____ 
 
 
3. Jeg har lett for å bli utmattet       ____ 
 
 
4. Utmattelse nedsetter min fysiske funksjonsevne    ____ 
 
 
5. Utmattelse skaper ofte problemer for meg     ____ 
 
 
6. Utmattelse fører til at jeg har dårlig fysisk utholdenhet   ____ 
 over lengre tid 
 
 
7. Utmattelse virker negativt inn på mine gjøremål    ____ 
 og forpliktelser 
 
 
8. Utmattelse er ett av mine tre mest plagsomme symptomer   ____ 
  
 
9. Utmattelse virker negativt inn på mitt arbeid,     ____ 
 min familie og mitt øvrige sosiale liv 
 
 
Ikke skriv under denne linjen        
IKM/UiTø 1995 
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Summary
Fatigue is a prevalent and substantial phenomenon in many patients with chronic
inflammatory diseases, often rated by patients as the most troublesome symptom
and aspect of their disease. It frequently interferes with physical and social func-
tions and may lead to social withdrawal, long-standing sick leave and disability.
Although psychological and somatic factors such as depression, sleep disorders,
pain and anaemia influence fatigue, the underlying pathophysiological mecha-
nisms by which fatigue is generated and regulated are largely unknown. Increas-
ing evidence points towards a genetic and molecular basis for fatigue as part of
the innate immune system and cellular stress responses. Few studies have focused
on fatigue in dermatological diseases. Most of these studies describe fatigue as a
phenomenon related to psoriatic arthritis and describe the beneficial effects of
biological agents on fatigue observed in clinical studies. It is therefore possible
that this problem has been underestimated and deserves more attention in the
dermatological community. In this review, we provide a definition and explana-
tion for chronic fatigue, describe some commonly used instruments for measur-
ing fatigue, and present hypothetical biological mechanisms with an emphasis on
activation of the innate immune system and oxidative stress. An overview of rele-
vant clinical studies covering the theme ‘psoriasis and fatigue’ is given.
What’s already known about this topic?
• Fatigue is prevalent in patients with chronic inflammatory diseases, cancer and
some neurological diseases.
• Depression, sleep disorders and pain influence fatigue.
• Genes and molecular signalling pathways are increasingly recognized as important
contributors to fatigue.
What does this study add?
• The relationship of fatigue with psoriasis disease activity is unclear.
• Biological drugs have a beneficial effect on fatigue in patients with psoriasis.
• More knowledge regarding the prevalence, severity and impact of fatigue in
patients with psoriasis is needed.
• Future therapeutic studies should include fatigue as an outcome variable.
Chronic fatigue is a frequent and often disabling phenomenon
that occurs in patients with chronic inflammatory and autoim-
mune diseases, cancer, neurological diseases and a number of
other conditions in which inflammation and/or cellular stress
occurs. Fatigue may be defined as ‘an overwhelming sense of
tiredness, lack of energy, and feeling of exhaustion’.1 For the
individual, as well as for society, it is important to gain
knowledge of the mechanisms through which fatigue is gener-
ated, and to develop effective treatment strategies.
Chronic fatigue syndrome (CFS)/myalgia encephalomyelitis
(ME) is a condition characterized by chronic fatigue and in
which no underlying disease or condition can be identified.
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However, in contrast to popular media reports and beliefs,
most people with chronic fatigue have an underlying primary
disease other than CFS/ME, with the latter reported in 0!2–
0!4% of subjects in community-based studies, and 2!6% of
patients in primary care.2,3
There is a complex inter-relationship between mental
depression, pain and fatigue. Also, sleep disorders in general,
and disrupted sleep in dermatological disorders such as atopic
dermatitis, have been linked to daytime sleepiness.4 However,
it is outside the scope of this review to cover these important
psychosocial aspects of fatigue in depth.
Fatigue varies in intensity between patients, and may be so
profound that it severely interferes with activities of daily liv-
ing, leading to long-standing sick leave and disability. Many
patients with chronic diseases consider fatigue their most trou-
blesome challenge.5
The frequently reported lack of an association between fati-
gue and disease activity in many studies is a paradox, and
apparently goes against common beliefs and conceptions.6 It
is clear that social and psychological factors play a role, but
the paradox may have a foundation in genetic and molecular
mechanisms that are crucial for the generation and regulation
of fatigue.7 Emerging evidence points to the innate immune
system as an important ‘fatigue generator’, brought on by
invading pathogens, autoimmune diseases, cancer or other
‘danger-signals’, as well as cellular stress responses.8
Many dermatological diseases and conditions demonstrate
inflammatory or autoimmune features, suggesting that fatigue
would be an accompanying phenomenon in a number of
chronic skin diseases. Also, psoriasis shares common pathways
of immune signalling with other inflammatory diseases
including psoriatic arthritis and rheumatoid arthritis (RA),
such as the interleukin (IL)-23/T helper cell (Th)17 axis.9–12
The proinflammatory cytokine IL-23 orchestrates T-cell-depen-
dent pathways of inflammation, and of special importance is
activation of the T-cell subtype Th17, which produces IL-17
and other proinflammatory cytokines.13,14
From this perspective, one would expect fatigue to be
common in dermatological diseases, but the literature on this
matter is sparse and deals mainly with the effect of biologi-
cal agents on fatigue reported as quality-of-life measures. It
is therefore both important and challenging to explore the
extent of this problem and identify how – and if – this
phenomenon interferes with the lives of patients with such
diseases.
What is fatigue?
Fatigue is a poorly understood phenomenon. It is abstract in
nature and has been described as ‘like water it slips away and
cannot be grasped’.15 Although everyone seems to recognize
it, fatigue is often less focused on, overlooked or underesti-
mated by clinicians,5,16 which may reflect there being no spe-
cific treatment for chronic fatigue.17
While fatigue is difficult to define and treat, it is also a
challenge to measure. Making it even more complex, there is
conceptual disagreement about whether chronic fatigue can be
consider a unidimensional phenomenon, or whether several
dimensions or subscales of fatigue exist, such as physical fati-
gue, muscular fatigue, mental fatigue, cognitive fatigue etc.
Arguments for the first view are that fatigue is a universal and
global experience that to varying degrees interferes with – or
has an impact on – different aspects of human life, including
traits or attributes associated with the disease. Arguments for
the latter comprehension of fatigue are that fatigue is a phe-
nomenon that more or less specifically influences the muscles,
brain, mood, initiative, physical activity etc., and should
therefore be considered a separate feature.18
Fatigue interferes with several aspects of life including emo-
tional, physical and social functioning. The burden of chronic
fatigue on society is high, primarily due to medical expenses,
sick leave and loss of work.19,20 In a qualitative study of
patients with primary Sjӧgren syndrome (pSS) where the
effects of medications on fatigue were examined, two themes
emerged after individual interviews.21 Patients clearly differen-
tiated fatigue from normal tiredness and described ‘a heavy
resistant body and ever present lack of vitality’ and ‘an unpre-
dictable, uncontrollable fluctuation in fatigue’. This differs
from the normal tiredness everyone feels after being exposed
to mental and physical stress, and fatigue does not respond to
rest as in a healthy individual. Chronic fatigue is therefore not
to be confused with tiredness.
Biological mechanisms of fatigue
A highly relevant model for fatigue may be sought in the so-
called ‘sickness behaviour’, which represents an adaptive and
complex response in humans and animals during the course
of an infection.22–24 Sick individuals demonstrate loss of appe-
tite, initiative, grooming and interest in other individuals.
They develop sleepiness and withdraw from normal social
activities.25 Fatigue is a prominent and dominant feature of
this response. Sickness behaviour seems to be deeply con-
served throughout evolution and, as such, it is not a maladap-
tive response but a subconscious strategy for the survival of
the individual and the species (the genome) during viral and
bacterial infections.
Activation of the innate immune system, which is found in
all plant and animal life and which provides the immediate host
immune response to infection and other immunological ‘dan-
ger’, may be a key regulator of fatigue in both acute and chronic
conditions. A number of studies show that sickness behaviour is
associated with proinflammatory cytokines such as IL-1b, IL-6
and tumour necrosis factor (TNF)-a.23,26 Among these
cytokines, IL-1b seems to have a pivotal role.27 IL-1b possesses
an early and strong proinflammatory effect and is secreted
mainly by activated monocytes, macrophages and dendritic
cells.28–30 IL-1b also reaches neuronal cells in the brain where it
binds to specific IL-1 receptors not causing inflammation, but
instead triggering the behavioural response.22,31
There is substantial experimental evidence from animal
models for an essential role of IL-1b in promoting sickness
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behaviour. IL-1b is rapidly transported through the blood–
brain barrier in injected animals, followed by rapid upregula-
tion of both IL-1 receptor antagonist and IL-1RI in the
brain.32–35 Also, injection of lipopolysaccharide into the
abdominal cavity activates lipopolysaccharide receptors on the
vagal nerve. Through neuronal signalling, this leads to produc-
tion of IL-1b in the brain, which is followed by the animal
exhibiting sickness behaviour.36 IL-1RI knockout mice are
resistant to the sickness-inducing effects of IL-1b.31 All these
observations point strongly to IL-1b as a key factor for sick-
ness behaviour and fatigue.
In humans, blockade of IL-1 in both RA and pSS results in
reduced fatigue.37 Also, a number of studies in different dis-
eases have demonstrated beneficial effects on fatigue by all bi-
ologics given (i.e. anti-TNF-a, anti-IL-6, anti-CD20 and the
cytotoxic T-lymphocyte-associated protein 4 Ig fusion protein,
abatacept).38–41
Oxidative stress is observed in acute and chronic inflamma-
tory diseases, and an association between chronic fatigue and
measures of oxidative stress has been demonstrated in CFS/ME
and systemic lupus erythematosus (SLE).42,43 There are no
such studies in dermatological disorders. Oxidative stress
results from an imbalance in which reactive oxygen species
(ROS) dominate over antioxidant defences.44–46 ROS are
important in the first line of defence against infections, as they
kill pathogens engulfed in cellular phagolysosomes.47 Chronic
inflammation causes a prolonged state of increased oxidative
stress, as reported in several diseases including psoriasis.48–51
Oxidative stress is part of the innate immune response and
is triggered by activation of pattern-recognition receptors on
innate immune cells such as macrophages and granulocytes.
To protect against the harmful effects of free radicals, cells
have developed a highly efficient system for combating the
cellular stress imposed by these reactive intermediates.8 The
exact mechanism for how oxidative stress is associated with
fatigue is unknown, but could involve activation of genes
important for cellular viability and protection. These genes
might also be responsible for development of fatigue across
different disease groups such as chronic inflammatory, neuro-
degenerative and neoplastic diseases.7
How to measure fatigue
Objective markers of fatigue do not exist, and all fatigue
instruments are based on self-reporting. Some tests attempt to
measure multiple aspects of fatigue, whereas others use a sin-
gle unidimensional approach.52 Also, some fatigue instru-
ments are designed to be used in specific diseases and thus
include disease-specific variables, for example the Parkinson
Fatigue Scale,53 Fatigue Impact Scale for multiple sclerosis54
and Profile of Fatigue for pSS.55 Other instruments are generic
and may be used across different disease entities, for example
the Fatigue Severity Scale (FSS)56 and the Functional Assess-
ment of Chronic Illness Therapy Fatigue subscale (FACIT-F).57
An overview of selected fatigue instruments is given in
Table 1.
In patients with psoriasis, studies of fatigue have been
assessed mainly by the use of the medical outcomes study short
form 36-item (SF-36) health survey.58 Only three studies have
used FACIT-F.59–61 The SF-36 health survey is a 36-item general
health status instrument. It contains subscales for eight domains,
where the Vitality subscale is supposed to cover energy and fati-
gue.58 A change of 3 or more points in the SF-36 Vitality sub-
scale score is considered clinically meaningful.62 The FACIT-F
self-administered questionnaire, originally developed to assess
fatigue associated with anaemia in patients with cancer, includes
13 questions regarding the impact of fatigue on patients’ activi-
ties over the past 7 days.57 The FACIT-F scores ranges from 0 to
52, with lower scores indicating more fatigue. A change in score
of at least 3 points is considered to be a minimally clinically
important difference.63
Fatigue in chronic diseases
Fatigue is the defining feature of CFS/ME. The syndrome is
diagnosed when no other disease or underlying condition can
be identified.64 No main causes of the syndrome have been
agreed upon, but a dominant hypothesis is that CFS is a con-
dition caused by the interaction between a common viral
infection and individual susceptibility factors such as genetic
and immune system dysfunction.65
Table 1 Selected generic self-reported fatigue instruments
Name of scale Dimension What is assessed No. of scale items No. of subscales Scale type
Fatigue Severity Scale56 Unidimensional Impact and
functional outcomes
9 1 7-point Likert




Unidimensional Severity and impact 13 1 5-point Likert
Medical Outcomes Study
Short Form 36-item scale (SF-36)58




Multidimensional Severity and impact 20 5 7-point Likert
Multidimensional Assessment
of Fatigue (MAF)112
Multidimensional Severity and impact 16 4 4–10-point Likert
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Fatigue accompanies inflammation and is frequently
reported among patients with a wide range of chronic inflam-
matory conditions. The prevalence of fatigue in patients with
RA, defined as a score of > 20 on the fatigue visual analogue
scale, was reported to be 41% in one study,66 and fatigue is
among the most commonly reported phenomena in multiple
sclerosis, pSS and SLE.67–70 In inflammatory diseases, as well
as in cancer-related fatigue, the fatigue has sometimes been
related to altered or increased proinflammatory cytokine pro-
duction.71,72 However, in general there seems to be a poor
correlation between disease activity and the severity of
fatigue.6,73–75 Lee et al.76 postulated that among patients with
RA there is a large subgroup with low levels of systemic
inflammation and low disease activity, yet high levels of fati-
gue and pain. This could be consistent with a chronic nonin-
flammatory central pain syndrome as seen in fibromyalgia,
which is a condition also associated with high levels of fati-
gue, pain and sleep problems.77 The underlying pathogenic
mechanism, as compared with those with high disease activity
inflammatory burden and high fatigue scores, could therefore
be somewhat different.
Cancer-related fatigue affects both patients with cancer and
cancer survivors.78 There are no major differences in fatigue
depending on cancer type, origin and disease stage.79 Interest-
ingly, cancer-related fatigue worsens during treatment with
cytostatic agents and radiation therapy, and may persist for years
in some cancer survivors after the cancer has been eradicated.80
Parkinson disease and cerebral stroke are examples of neuro-
logical conditions with no clear inflammatory component, and
in which fatigue is common and may be debilitating.81 In cere-
bral stroke, it is possible that there is a disturbance of neuronal
circuits within the basal ganglia, thalamus and cerebral cortex,
while the fatigue mechanisms in neurodegenerative diseases are
less clear, but might well be due to cellular stress responses.82,83
Confounding factors
Depression, sleep disorders and pain are confounding factors
to fatigue. Fatigue is strongly associated with depression and
vice versa.84–86 There is an overlap in symptomatology
between fatigue and depression, but fatigue also appears with-
out depression.68 Both depression and fatigue in chronic
inflammatory disorders, as well as in depressive diseases, have
been associated with proinflammatory cytokines.87 Intrigu-
ingly, patients with chronic fatigue are less responsive to anti-
depressant drugs than depressed patients.88 Notably, several
biological agents used in chronic inflammatory disorders have
shown improvement in both depression and fatigue scores.89–91
Some evidence indicates that IL-1 and TNF-a may play a role in
the regulation of sleep.92 The clinically interesting question is
why these behavioural alterations present more easily and are
more severe in some individuals than in others.
Fatigue in psoriasis
Psoriasis vulgaris (plaque psoriasis) is an immune-mediated
chronic inflammatory disease affecting about 2% of the
world’s population.93 The inflammation is thought to be a
consequence of a T-cell-mediated immune response to an as-
yet unidentified autoantigen. Several lines of evidence suggest
an important role for IL-17 in the pathogenesis of psoriasis, as
well as in psoriatic arthritis and other chronic inflammatory
disorders.94 Psoriasis may have a major impact on a patient’s
life, especially when the disease is moderate to severe.95
While psychosocial aspects have been widely studied in der-
matological diseases, less is known about fatigue.96 For an
overview of genuine studies of fatigue in psoriasis, see
Table 2. The majority of data regarding this phenomenon are
derived from the Vitality subscale of the SF-36, a general mea-
sure of health-related quality of life. This subscale consists of
only four questions, providing some indications of fatigue
(Table 1). One study using the SF-36 in dermatological outpa-
tient clinics in Norway reported significantly lower scores than
the general norms on eight subscales of the SF-36, and higher
levels of psoriasis-specific symptoms (itching, burning, scal-
ing, suppuration, stinging and joint pain) were significantly
related to all of the SF-36 subscales.97 It was not stated
whether some patients also had psoriatic arthritis.
Table 2 Genuine studies on fatigue in psoriasis
Study Design Fatigue instrument Outcome (mean)
Rapp (1999)113 Postal questionnaire study where scores of 317 patients
with psoriasis were compared with those from 10
different health conditions
SF-36 VS Vitality subscale 45!4
Wahl (2000)97 283 patients with psoriasis were included and scores
compared with general populations norms
SF-36 VS Vitality subscale 48!2
Evers (2005)96 Questionnaires administered to 128 outpatients with
psoriasis
VAS-Fatigue VAS-Fatigue 3!8
Verhoeven (2007)114 Postal questionnaire study where scores of 112 patients
with psoriasis registered in general practice were
compared with those from nine other skin conditions
VAS-Fatigue VAS-Fatigue 3!2, 28% reported
severe fatigue (VAS > 5)
Jankovic (2011)115 Questionnaires administered to 110 outpatients with
psoriasis
SF-36 VS Vitality subscale 48!9
SF-36 VS, Medical Outcomes Study Short Form 36-item scale (SF-36) Vitality subscale; VAS, visual analogue scale.
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The prevalence of psoriatic arthritis in patients with psoriasis
is estimated to be as high as 30%.98 Few comparative studies of
health-related quality-of-life measures between patients with
psoriasis with and without arthritis have been performed. In
one study, patients with psoriasis without arthritis were found
to have less fatigue, as measured by the FSS and the Vitality sub-
scale of the SF-36, compared with patients with arthritis.99 In
this study, the mean Dermatology Life Quality Index of patients
with psoriasis was 7!7, indicating a moderate effect on patients’
lives. These findings are in contrast to the 2005 Spring US
National Psoriasis Foundation Quality of Life study, where no
differences were found in overall health-related quality of life
between these groups.100 This study was conducted by tele-
phone interviews, which might affect the quality of the data
collected. To what degree arthritis influences fatigue in patients
with psoriasis is therefore difficult to assess.
The majority of data on fatigue in patients with psoriasis
arises from therapeutic clinical trials in which patients with
arthritis have frequently been included, and these studies often
lack information on the number of subjects with arthritis (for
an overview see Table 3).38,59–61,101–109 Patients who were
included generally had moderate-to-severe psoriasis with a
mean Psoriasis Area and Severity Index (PASI) > 14. All thera-
peutic studies in psoriasis employing biological agents have
demonstrated a beneficial effect on the Vitality subscale of the
SF-36. Only three studies used the FACIT-F, but revealed a
clinically meaningful reduction of fatigue with the TNF-a
inhibitors adalimumab or etanercept.59–61 Tyring et al.
reported less fatigue as measured with the FACIT-F, which
was associated with improvements in joint and skin pain with
the use of etanercept. In this study, up to 35% of the patients
included had arthritis, and it was debated whether the effect
of etanercept on fatigue could be attributed to an effect on
psoriatic arthritis.91
To the best of our knowledge, no studies have investigated
fatigue in relation to disease activity in patients with psoriasis
who did not have arthritis. Also, because most patients with
psoriasis have low C-reactive protein or erythrocyte sedimen-
tation rate, it is difficult to evaluate the influence that psoriatic
inflammation might have on fatigue. Finally, the prevalence
and the degree of fatigue in a general population with psoria-
sis compared with a healthy control group remains to be
studied.
Conclusions
Fatigue is an important feature of all inflammatory diseases. In
psoriasis and other dermatological diseases, knowledge of fati-
gue is sparse and could represent a major but hidden problem
in a considerable number of patients with psoriasis. Moreover,
is it not known whether fatigue in patients with psoriasis is
related to the extent of the disease (PASI scores) or other dis-
ease characteristics. It is therefore important to determine the
prevalence, severity and impact of fatigue because this will
add to the clinician’s understanding and management of
patients with psoriasis. Also, future therapeutic studies should
include fatigue as an outcome variable.
The psychological and social factors that influence fatigue
are outside the scope of this review. These issues need to be
reviewed and synthesized as part of future research projects.
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Summary
Background Fatigue is associated with various chronic inflammatory diseases, but
few studies have focused on its occurrence in psoriasis.
Objectives To describe fatigue prevalence and degree among patients with
chronic plaque psoriasis vs. age- and sex-matched healthy subjects, and to
examine how fatigue is influenced by essential clinical and demographic
factors.
Methods In 84 patients and 84 healthy subjects, fatigue severity was assessed using
three different generic fatigue instruments: the fatigue Visual Analogue Scale
(fVAS), the Fatigue Severity Scale (FSS) and the Short Form 36 (SF-36) Vitality
scale. Cut-off scores for clinically important fatigue were defined as ≥ 4 for FSS,
≥ 50 for fVAS and ≤ 35 for the SF-36 Vitality scale. Disease activity was evalu-
ated using the Psoriasis Area and Severity Index (PASI), and the impact on quality
of life with the Dermatology Life Quality Index (DLQI).
Results Patients and healthy control subjects, respectively, showed median fVAS
scores of 51 [interquartile range (IQR) 21–67] and 11 (IQR 3–20); FSS scores of
4 (IQR 2!5–5!3) and 1!6 (IQR 1!1–2!2); and SF-36 Vitality scores of 43 (IQR
25–85) and 73 (IQR 65–85). The rates of clinically important fatigue among
patients vs. healthy controls, respectively, were 51% vs. 4% (fVAS); 52% vs. 4%
(FSS); and 42% vs. 2% (SF-36 Vitality) (P < 0!001 for all differences). Fatigue
was associated with DLQI scores, but not PASI scores, in univariate analysis but
not in multivariate analysis.
Conclusions Nearly 50% of patients with psoriasis suffered from substantial fatigue.
Fatigue severity was associated with smoking, pain and depression, but not with
psoriasis severity.
What’s already known about this topic?
• Fatigue is prevalent in patients with chronic inflammatory diseases, cancer and
some neurological diseases.
• Depressive mood and pain are strong factors influencing fatigue.
• Emerging evidence points to genes and molecular signalling pathways as important
contributors to fatigue.
What does this study add?
• Clinically significant fatigue occurs in nearly 50% of patients with psoriasis.
• Objective measures of psoriasis disease activity do not correlate with fatigue
severity.
• There is a need for more research to understand the factors that generate and regu-
late fatigue in psoriasis.
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Fatigue, defined as ‘an overwhelming sense of tiredness, lack
of energy, and a feeling of exhaustion’,1 is a prevalent phe-
nomenon among many patients with chronic inflammatory
and autoimmune conditions, such as inflammatory bowel dis-
ease, rheumatoid arthritis, primary Sj€ogren syndrome and sys-
temic lupus erythematosus.2–4 In fact, patients with these
conditions often identify fatigue as the most troublesome
aspect of their disease, as it interferes with physical and social
activities and frequently leads to social withdrawal and long-
term sick leave.5
In clinical experience, fatigue is a common complaint
among many patients with the chronic inflammatory
immune-mediated disease psoriasis. However, few studies
have explored this association in depth, and the majority of
available data are from therapeutic clinical trials investigating
new biological agents. Such studies often include patients with
psoriatic arthritis, a condition that could possibly influence the
severity of fatigue. There remains a lack of unbiased investiga-
tions focusing on how fatigue presents and is experienced by
patients with psoriasis alone.
Fatigue associated with other diseases is clearly influenced
by pain and depression, but such a relationship is not docu-
mented in psoriasis. Moreover, the impact of disease activity
on fatigue in inflammatory diseases remains a controversial
issue. Some investigators claim that fatigue increases with high
disease activity, while others have not confirmed such a rela-
tionship.6–11 This issue has not yet been thoroughly studied in
patients with psoriasis. Thus, there remains a need to elucidate
the extent and severity of fatigue in psoriasis, and to uncover
any genetic basis and signalling mechanisms that lead to
fatigue.12
Here we performed a controlled study with the aim of
describing fatigue prevalence and severity among patients with
chronic plaque psoriasis. We further investigated how fatigue
was related to essential clinical and demographic factors.
Patients and methods
Patients
Eligible patients were consecutively identified based on referral
letters to the outpatient clinic, Department of Dermatology,
Stavanger University Hospital, from 6 November 2012 to 19
May 2015. Additionally, three patients were recruited from
the follow-up clinic. The inclusion criteria were white Norwe-
gian-speaking individuals, age > 18 years and a clinical diag-
nosis of chronic plaque-type psoriasis. Patients were excluded
if they had other types of psoriasis (guttate, unless associated
with a typical plaque of psoriasis; erythrodermic; or pustular
psoriasis), or prior history of cancer, psoriatic arthritis,
chronic inflammatory diseases other than psoriasis, or
untreated hyper- or hypothyroidism. Written information
about the study was posted to the patients prior to their
scheduled outpatient appointment.
A total of 120 patients were screened for potential partici-
pation; of these 84 were included (Fig. 1).
Assessed for eligibility n = 120  
Included n = 84 
Not meeting inclusion criteria n = 30 
Other dermatological disease n = 22 
History of psoriatic arthritis n = 3 
Nonwhite  n = 2 
Acute infection at time of screening n = 2 
History of cancer n =  1 
Lack of age- and sex-matched healthy subjects n = 5 
Withdrawn consent n = 1 
Fig 1. Flowchart of included patients.
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Healthy subjects
The 84 healthy control subjects were predominantly recruited
from acquaintances of the patients. Some control subjects
(8%) were also recruited from employees of the service divi-
sion of the hospital and their acquaintances. The healthy con-
trol subjects were matched by age (" 3 years) and sex with
the individual patients, and fulfilled the same inclusion and
exclusion criteria as the patients, except for the diagnosis of
psoriasis.
Demographic and selected clinical data
The patient and control groups were similar with regard to
education level, marital status and comorbidities, except for
hypertension (Table 1). Compared with healthy controls,
patients exhibited a somewhat higher body mass index (BMI)
and significantly higher rate of smoking. Median [interquartile
range (IQR)] Psoriasis Area and Severity Index (PASI) score
was 6!0 (4!5–7!3) and Dermatology Life Quality Index (DLQI)
score was 10 (6–13). Among the patients, 70% had a PASI
score < 7, indicating mild disease.13 Only two patients were
taking oral medication (methotrexate or acitretin). The
remaining 82 patients received, at most, topical treatment, but
no systemic treatment. All except for one were na€ıve to bio-
logical medications. Disease duration of > 10 years was
reported by 73% of the patients.
Hypertension was defined as a systolic blood pressure
≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg or receiv-
ing antihypertensive therapy at the time of examination. Other
comorbidities were also noted, including history of diabetes,
overt cardiovascular disease (e.g. myocardial infarction, angina
pectoris, stroke, transient ischaemic attack or cardiac dysrhyth-
mia), migraine or respiratory disease (e.g. asthma or chronic
obstructive pulmonary disease).
Clinical assessment and disease activity
All participants underwent a general clinical examination dur-
ing which we collected demographic and clinical data, and
recorded information about medical history, current medica-
tion and tobacco smoking (Table 1).
Psoriasis severity was evaluated using the PASI.14 The PASI
assesses psoriasis severity and extent by accounting for the
percentage area affected by psoriasis in four body regions
(head and neck, upper limbs, trunk and lower limbs), as well
as the intensity of the plaque redness, thickness and scaling.
The final PASI result is a single severity score ranging from 0
to 72.13 Severity has been categorized as follows: PASI < 7
indicates mild plaque psoriasis; PASI 7–12 indicates moderate
plaque psoriasis; and PASI > 12 indicates severe psoriasis.13
The DLQI is a patient-reported outcome measuring the
impact of the dermatological disease on the patient’s quality
of life (QoL). The DLQI is simple, practical and widely used
instrument consisting of a 10-item questionnaire that evaluates
the impact of skin disease on QoL with a score ranging from
0 (no impairment) to 30 (maximal impairment). A
DLQI > 10 implies a skin disease with a considerable influ-
ence on the patient’s QoL.15
Fatigue measures
Fatigue severity was assessed using three different generic and
unidimensional fatigue instruments: the fatigue Visual Ana-
logue Scale (fVAS);16 the Fatigue Severity Scale (FSS);17 and
the Vitality subscale of the Short Form 36 (SF-36 Vitality).18






(n = 84) P-value
Demographics
Mean " SD age
(years)
45 " 14 45 " 14




Current smoking 25 (30) 13 (15) 0!04
Educational status
(college/university)
35 (42) 46 (55) 0!07




27 (24–30) 26 (23–29) 0!04
Median (IQR) PASI 6!0 (4!5–7!3)
PASI < 7 59 (70)




2 (0!7–4!9) 1!3 (0!5–3!3) 0!05
Median (IQR)
Hb (g 100 mL#1)
15 (14–16) 15 (14–16) 0!72
Median (IQR)
GFR
(mL min#1 1!73 m#2)
98 (89–108) 96 (81–109) 0!10
Comorbid disease
Hypertension 44 (52) 28 (33) 0!01
Diabetes 4 (5) 1 (1) 0!38
CVD 5 (6) 1 (1) 0!22
Respiratory disease 8 (10) 5 (6) 0!58
Depression
(HADS-D ≥ 8)a
20 (24) 1 (1) < 0!001
Medication
Antidepressants 4 (5) 0 (0) 0!13
Levothyroxine 1 (1) 0 (0) 1!00
Immunosuppressive
drugs
2 (2) 0 (0) 0!50
Beta blockers 8 (10) 2 (2) 0!11
Data are n (%) unless otherwise indicated. IQR, interquartile
range; BMI, body mass index; PASI, Psoriasis Area and Severity
Index; DLQI, Dermatology Life Quality Index; CRP, C-reactive
protein; Hb, haemoglobin, GFR, glomerular filtration rate; CVD,
cardiovascular disease; HADS-D, depression subscale of the
Hospital Anxiety and Depression Scale. an = 82.
© 2017 British Association of Dermatologists British Journal of Dermatology (2017) 177, pp505–512
Fatigue in psoriasis, I.M. Skoie et al. 507
During the examinations of the subjects, information was
given about comprehension of the questions and how to score
the fatigue instruments.
The FSS is an instrument that includes nine statements
regarding the patient’s fatigue over the last 2 weeks. To each
item, the patients assign a score of between 1 (completely dis-
agree) and 7 (completely agree), and these scores are summed
and divided by nine to generate the FSS score. A higher FSS
score indicates greater fatigue. An FSS score of 3 or 4 has been
used as the cut-off to define clinically important fatigue. In
the present study, we applied a conservative cut-off score of
≥ 4.19
The fVAS utilizes a 100-mm-long horizontal line with verti-
cal anchoring lines labelled ‘no fatigue’ at the left end
(0 mm) and ‘worst possible fatigue’ at the right end
(100 mm). Patients are asked to rate their fatigue level by
placing a marker at the point along the line that best repre-
sents their perception of fatigue over the last week. In this
study, we used a conservative cut-off value, with clinically
important fatigue defined by an fVAS score of ≥ 50 mm.20
The vitality subscale of the SF-36 questionnaire comprises
four questions about energy and fatigue. The subscale score is
calculated according to standard procedures, yielding score
values between 0 to 100, with higher scores indicating greater
functioning.21 Clinically important fatigue was defined by a
vitality score of ≤ 35, in accordance with previous data show-
ing that this cut-off indicates relevant fatigue.22
Depression and pain
To detect concomitant depressive mood, we used the depres-
sion subscale of the Hospital Anxiety and Depression Scale
(HADS-D).23 The HADS questionnaire comprises seven items
on anxiety and seven on depression, which are each answered
with a number from 0 to 3, and these responses are summed
to obtain the anxiety and depression subscales, respectively. A
score of ≥ 8 indicates possible depression and a score of ≥ 11
indicates probable depression. A HADS-D score of ≥ 8 was
previously found to be adequate as a cut-off for depression
and was used as the cut-off in this study.24
Pain was assessed using the bodily pain subscale of the
SF-36 (SF-36 Pain). The SF-36 Pain is a two-item scale that
assesses bodily pain intensity and the interference of pain
with normal activities during the last 4 weeks. The score
ranges from 0 to 100, with higher scores representing less
pain.25
Statistical analyses
Our calculations revealed that we required a minimum sam-
ple size of 33 patients and 33 healthy subjects to detect a
meaningful difference in fatigue measured as a fVAS score of
25, with a power of 80 and significance of 5%. We consid-
ered this a robust measure as a prior study of primary
Sj€ogren syndrome had applied a 20% reduction in fVAS
score.26
Most continuous descriptive data were not normally dis-
tributed, and are thus presented as median (IQR) and as n (%)
for categorical data. For comparisons between two groups of
paired data, we used the Wilcoxon signed-rank test for contin-
uous data and the McNemar test for categorical data. Associa-
tions between fatigue and possible influential factors were first
assessed using linear regression models for determination of
estimated effect (beta) and 95% confidence interval (CI),
P-value for hypotheses of no effect and R2 value to evaluate
model fit. Variables that showed P-values < 0!25 in univariate
analyses were subsequently included in multiple regression
analyses. The final regression model included only explanatory
variables with a P-value < 0!05 in stepwise backward selec-
tion, and it was determined that no excluded variable would
attain this level of significance and/or substantially change
other effect estimates when subsequently included in forward
selection. Most statistical analyses were performed using SPSS
Statistics version 23 (IBM, Armonk, NY, U.S.A.). In situations
with zero count categories, McNemar tests were performed
using Vassarstats online calculator (http://vassarstats.net/prop
corr.html).
All three fatigue instruments were used to assess fatigue
severity and prevalence among patients and healthy subjects.
However, as visual analogue scales are considered to provide a
more optimal scoring spread, fVAS was used for further statis-
tical analyses. Regression analyses applying FSS and SF-36
Vitality as dependent variables are given in Tables S1 and S2
(see Supporting Information). The analyses excluded data for
one patient and one healthy subject owing to missing HADS-
D scores.
Ethical considerations
This study was approved by the Regional Committee for Med-
ical Research Ethics in Norway (REK vest 2010/1455). All
participants gave their written informed consent, and the
study was conducted in accordance with the latest revision of
the Declaration of Helsinki.
Results
Fatigue severity and prevalence
On all three fatigue instruments utilized, patients showed sig-
nificantly higher fatigue scores than age- and sex-matched
healthy subjects. In the patients and healthy subjects, respec-
tively, median fVAS scores were 51 (21–67) and 11 (3–20);
FSS scores were 4 (2!5–5!3) and 1!6 (1!1–2!2); and SF-36
Vitality subscale scores were 43 (25–55) and 73 (65–85)
(Fig. 2). Based on the defined cut-off values, the rates of clini-
cally important fatigue in patients vs. healthy subjects, respec-
tively, were 51% vs. 4% (fVAS); 52% vs. 4% (FSS); and 42%
vs. 2% (SF-36 Vitality), with all differences being highly sig-
nificant (P < 0!001) (Fig. 3). No difference in fatigue preva-
lence was seen between patients with mild disease (PASI < 7)
vs. moderate-to-severe disease (PASI ≥ 7) (P = 0!92).
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Factors associated with fatigue (fatigue Visual Analogue
Scale)
Selected demographic and clinical variables were tested in uni-
variate analyses (Table 2). Fatigue was associated with smok-
ing, DLQI, SF-36 Pain and HADS-D, and was not associated
with age, sex, psoriasis duration, education level, BMI, C-reac-
tive protein (CRP), haemoglobin, hypertension or other
comorbidities, or PASI scores.
Variables with P-values < 0!25 were included in multiple
regression analyses. Stepwise backward and forward model
selection was used to construct a final multiple regression
model (Table 3) that explained 43% of the variance in fatigue.
In this model, higher fatigue was associated with current
smoking, lower SF-36 Pain scores (more pain) and higher







































Fig 2. Median fatigue Visual Analogue Scale (fVAS), Short Form 36
(SF-36) Vitality and Fatigue Severity Scale (FSS) scores measured in















































P < 0·001 P < 0·001
Fig 3. Percentages of subjects with clinically important fatigue, as
determined using fatigue Visual Analogue Scale (fVAS), Fatigue
Severity Scale (FSS) and Short Form 36 (SF-36) Vitality, among the 84
patients with psoriasis and the 84 age- and sex-matched healthy
subjects.
Table 2 Associations between fatigue Visual Analogue Scale and
selected demographic and clinical variables among patients with
psoriasis (n = 83)a
b 95% CI P-value
Demographics
Age (years) #0!28 #0!72 to 0!15 0!20
Male sex 1!92 #10!54 to 14!38 0!76
Psoriasis duration
(years)
#0!01 # 0!51 to 0!48 0!96
Current smoking 14!94 1!98–27!91 0!02
Education level
(college/university)
#4!33 #16!59 to 7!91 0!48
Clinical data
BMI (kg m#2) #0!42 #1!38 to 0!53 0!38
PASI 0!28 #1!54 to 2!10 0!76
DLQI 2!01 1!11 to 2!91 < 0!001
Biochemical data
CRP (mg L#1) 0!06 #1!30 to 1!41 0!94
Hb (g 100 mL#1) 2!63 #2!79 to 8!04 0!34
Comorbid disease
Hypertension 1!51 #10!64 to 13!66 0!81
Diabetes #2!46 #30!78 to 25!86 0!86
CVD 0!71 #24!79 to 26!20 0!96
Respiratory disease 6!13 #14!38 to 26!64 0!55
Pain
SF-36 Pain #0!55 #0!76 to #0!34 < 0!001
Mood disturbance
HADS-D 4!24 2!81–5!67 < 0!001
Results from univariate linear regression analyses. CI, confidence
interval; BMI, body mass index; PASI, Psoriasis Area and Severity
Index; DLQI, Dermatology Life Quality Index; CRP, C-reactive
protein; Hb, haemoglobin; CVD, cardiovascular disease; SF-36
Pain, Short Form 36 Bodily Pain Scale; HADS-D, the depression
subscale of the Hospital Anxiety and Depression Scale. aOne
patient excluded owing to missing HADS-D score.
Table 3 Factors associated with fatigue Visual Analogue Scale for
patients with psoriasis (n = 83)a
b 95% CI P-value
Current smoker 11!81 1!57–22!06 0!02
SF-36 Pain #0!36 #0!56 to #0!16 0!001
HADS-D 3!11 1!68–4!54 < 0!001
Results from the final multiple linear regression model. Final
model (n = 83), R2 43%. CI, confidence interval; SF-36 Pain,
Short Form 36 Bodily Pain Scale; HADS-D, Depression subscale
of the Hospital Anxiety and Depression Scale. aOne patient
excluded owing to missing HADS-D score.
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education level, BMI, CRP, haemoglobin, hypertension or
other comorbidities, PASI scores or disease duration. Further,
we observed no signs that any of these variables were impor-
tant confounding factors for the variables in the final model.
Notably, the significant positive association between fVAS and
DLQI detected in univariate analyses disappeared following
adjustment for the other variables.
The full model, including all of the tested variables listed in
Table 2, explained 51% of the variance (Table 4). When
smoking, SF-36 Pain, DLQI and HADS-D were excluded from
the model, only 9% of the variance in fVAS was explained by
demographic and objective clinical observations (age, sex,
psoriasis duration, education level, BMI, PASI, CRP, haemoglo-
bin, hypertension or other comorbidities) (Table 5). Inclusion
of smoking and pain in the model explained an additional 4%
and 32%, respectively.
Discussion
The major finding of the present study was that approximately
50% of patients with psoriasis suffered from fatigue,
consistent with previous observations in other chronic inflam-
matory and autoimmune diseases.2,4,27 This rate was consider-
ably higher than the rate of fatigue among healthy age- and
sex-matched individuals, indicating that fatigue is a prevalent
problem associated with psoriasis. Our results were similar
with all three fatigue instruments – fVAS, FSS and SF-36 Vital-
ity – and thus provide a good estimation of the size of the
problem.
Our second important finding was that objective measure-
ments of disease activity and inflammatory variables, such as
PASI and CRP, were not significantly associated with fatigue
severity. This result is in agreement with prior studies that
have applied generic and unidimensional fatigue instruments
not containing the elements of disease-associated factors that
are intrinsic to most disease-specific fatigue instruments. It is
commonly thought that higher disease activity will correlate
with greater fatigue. However, the lack of association between
fatigue severity and disease activity or inflammatory variables
suggests that the fatigue response may be controlled by path-
ways other than genuine proinflammatory pathways.
Emerging evidence suggests that the innate immune system
may be an important ‘fatigue generator’.28–31 When patho-
gens or other danger signals activate innate immunity cells,
proinflammatory cytokines cross the blood–brain barrier into
the brain, triggering an evolutionarily conserved behavioural
response (i.e. sickness behaviour), of which fatigue is a
prominent feature. In chronic inflammatory conditions, this
signalling is constantly active, leading to chronic fatigue.32 As
Table 4 Fully adjusted associations between fatigue Visual Analogue
Scale and selected demographic and clinical variables among patients
with psoriasis (n = 83)a
b 95% CI P-value
Demographics
Age (years) #0!39 #0!87 to 0!09 0!11
Male sex 1!08 #12!91 to 15!07 0!89
Psoriasis duration (years) #0!12 #0!60 to 0!35 0!60
Current smoking 10!52 #2!28 to 23!32 0!11
Education level
(college/university)
4!54 #6!62 to 15!69 0!42
Clinical data
BMI (kg m#2) #0!67 #1!82 to 0!49 0!25
PASI #0!79 #2!74 to 1!17 0!42
DLQI 0!28 #1!03 to 1!59 0!67
Biochemical data
CRP (mg L#1) 0!91 #0!63 to 2!46 0!24
Hb (g 100 mL#1) 0!09 #5!77 to 5!94 0!98
Comorbid disease
Hypertension 9!94 #2!44 to 22!32 0!11
Diabetes #6!19 #30!26 to 17!88 0!61
CVD 4!13 #17!10 to 25!36 0!70
Respiratory disease 10!06 #8!37 to 28!48 0!28
Pain
SF-36 Pain #0!41 #0!69 to #0!13 0!005
Mood disturbance
HADS-D 2!87 1!11–4!62 0!002
Results from the linear regression model, including all candidate
variables. Full model (n = 83), R2 51%. CI, confidence interval;
BMI, body mass index; PASI, Psoriasis Area and Severity Index;
DLQI, Dermatology Life Quality Index; CRP, C-reactive protein;
CVD, cardiovascular disease; SF-36 Pain, Short Form-36 Bodily
Pain Scale; HADS-D, Depression subscale of the Hospital Anxiety
and Depression Scale. aOne patient excluded owing to missing
HADS-D score.
Table 5 Adjusted associations between fatigue Visual Analogue Scale
and the candidate variables for the patients with psoriasis (n = 83)a
when current smoking, Short Form 36, Dermatology Quality Life
Index, and Hospital Anxiety and Depression Scale are excluded
b 95% CI P-value
Demographics
Age (years) #0!50 #1!08 to 0!09 0!09
Male sex #3!19 #20!33 to 13!10 0!71
Psoriasis duration (years) 0!27 #0!32 to 0!85 0!37
Education level
(college/university)
#3!81 #17!47 to 9!85 0!58
Clinical data
BMI (kg m#2) #1!16 #2!62 to 0!31 0!12
PASI 0!42 #1!62 to 2!46 0!68
Biochemical data
CRP (mg L#1) 1!09 #0!95 to 3!13 0!29
Hb (g 100 mL#1) 2!74 #4!68 to 10!16 0!46
Comorbid disease
Hypertension 7!47 #8!58 to 23!52 0!36
Diabetes 2!95 #28!30 to 34!20 0!85
CVD 1!57 #26!15 to 29!30 0!91
Respiratory disease 12!75 #10!42 to 35!92 0!28
Results from multiple linear regression analysis. Full model
(n = 83), R2 9%. CI, confidence interval; BMI, body mass index;
PASI, Psoriasis Area and Severity Index; CRP, C-reactive protein;
Hb, haemoglobin; CVD, cardiovascular disease. aOne patient
excluded owing to missing HADS-D score.
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inflammation is upregulated, mechanisms immediately start to
control and downregulate this response. Immune downregula-
tion and cellular defence mechanisms against oxidative stress
and other dangers could potentially act as redundant and
strong triggers of fatigue. This hypothesis is supported by our
recent finding of elevated heat shock protein 90alevels in
patients with severe fatigue.30
Another observation that may support this theory is that
smokers reported more fatigue than nonsmokers. Others have
also reported this association.33 Smoking causes oxidative
stress, with subsequent increases of antioxidative defence and
other mechanisms to protect cellular life. Fatigue is associated
with oxidative stress in many chronic inflammatory disor-
ders.34 On a pathophysiological level, this may contribute to
the greater prevalence of fatigue among smokers. However,
history of depression is more common among smokers than
nonsmokers, and this relationship could also contribute to the
association between smoking and fatigue.35
Fatigue was most strongly influenced by depressive mood
and pain, which is a well-known constellation in both chronic
inflammatory and noninflammatory disorders.36,37 In the
complex relationship between fatigue and depression, at least
three interrelated factors are regarded as important. Firstly,
there is an overlap in phenomenology between fatigue and
depression. Secondly, questionnaires used to assess fatigue and
depression often share similar wording, tapping more or less
the same dimensions, and leading to a causal chain with a
‘false’ association between the two factors. Notably, compared
with depression, fatigue seems to be less responsive to antide-
pressant treatment.38 Thirdly, increasing evidence from animal
and human studies suggests that depression and fatigue may
be signalled through shared molecular pathways.39,40
Chronic pain influences feelings of energy and coping abili-
ties, but the exact mechanisms that lead to fatigue remain
unclear. The process may involve psychological and adaptive
factors, including the development of depressive mood. In
psoriasis, muscular and articular complaints frequently occur
in the absence of clinical signs of arthritis, and are not related
to psoriasis severity or extent.41 Further studies are needed to
explore the complex relationship between depressed mood,
pain and fatigue in psoriasis, as well as in other conditions.
Fatigue was not associated with age or disease duration.
This is in accordance with previous findings in patients with
psoriatic arthritis and other chronic inflammatory diseases.2,7
The present results also suggest that fatigue was independent
of the extent and severity of skin inflammation. Psoriasis
severity is defined by the signs and symptoms, disease history
and the disease’s effects on the patient’s QoL. A patient with
very few psoriasis plaques or limited psoriasis in special loca-
tions such as the scalp, genitals, hands and feet may neverthe-
less be devastated by the disease. Accepted clinical tools for
defining psoriasis severity include the PASI, body surface area
and the DLQI, which can be used individually or in combina-
tions.15,42,43 While the PASI is an objective measure of psoria-
sis severity, the DLQI includes elements related to mood, pain
and fatigue. Thus, it is unsurprising that DLQI score covaried
with fatigue in univariate analyses, and that this association
disappeared when depressive mood and pain were introduced
in the multiple regression analyses. The choice of an objective
disease activity instrument is crucial for correctly interpreting
the effects of psoriasis severity on fatigue.
One major strength of the current study was the matched
case–control design that prevented confounding effects of age
and sex. Additional strengths included the assessment using
well-validated measures of fatigue, and the relatively large and
well-characterized study population. All patients were inter-
viewed and assessed by the same researcher, and were consec-
utively recruited from the same clinic. Moreover, all patients
except for one were na€ıve to biological medication. The study
also had several limitations. Firstly, the study patient popula-
tion mainly comprised patients with psoriasis with PASI scores
indicating mild disease. Another limitation was the lack of fol-
low-up or repeated examination. Furthermore, we did not
measure sleep disruption, itch or physical activity, which
could potentially be important determinants of fatigue. We
selected cut-off values that have been used in previous studies
(VAS > 50, FSS > 4, SF-36 < 35), and the prevalence
obtained with fVAS matched the results with SF-36 and FSS.
However, the validity of these cut-off values is debatable, par-
ticularly as it is not logical to dichotomize this complex beha-
vioural response into simply ‘fatigue’ or ‘no fatigue’.
In conclusion, the present results indicate that nearly 50%
of patients with psoriasis suffer from fatigue, and that fatigue
was strongly associated with pain and depression. Fatigue was
not significantly associated with markers of disease activity.
These findings suggest a need to accept fatigue as an impor-
tant and prevalent aspect of psoriasis. A better understanding
of the link between psoriasis and fatigue could promote the
development of better care and self-management options for
these patients, and possibly lay the foundation for more effec-
tive therapeutic approaches in the future.
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